Notes_NNS to_TO the_DT financial_JJ statements_NNS 1_CD Segmental_JJ analysis_NN by_IN business_NN sector_NN 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Sales_NNS Amersham_NNP Health_NNP 947.7_CD 922.0_CD Amersham_NNP Biosciences_NNP 670.5_CD 680.5_CD 1,618.2_CD 1,602.5_CD Included_VBN within_IN Amersham_NNP Health_NNP is_VBZ the_DT groups_NNS share_NN of_IN Nihon_NNP Medi-Physics_NNP NMP_NNP joint_JJ venture_NN sales_NNS during_IN the_DT year_NN of_IN 80.5_CD m_NN 2001_CD 87.3_CD m._NN Total_JJ operating_NN profit_NN before_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN Amersham_NNP Health_NNP 255.6_CD 240.9_CD Amersham_NNP Biosciences_NNP 75.3_CD 72.4_CD Corporate_JJ and_CC other_JJ 21.1_CD 20.8_CD 309.8_CD 292.5_CD The_DT following_VBG table_NN shows_NNS operating_VBG profit_NN after_IN allocation_NN of_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN ._.
The_DT exceptional_JJ items_NNS charged_VBN in_IN 2002_CD relate_VBP nil_NN 2001_CD 8.5_CD m_NN to_TO Amersham_NNP Health_NNP ,_, nil_NN 2001_CD 2.6_CD m_NN to_TO Amersham_NNP Biosciences_NNPS and_CC nil_NN 2001_CD 2.4_CD m_NN income_NN to_TO Corporate_JJ and_CC other_JJ ._.
Amortisation_NNP charged_VBD on_IN goodwill_NN in_IN 2002_CD relates_VBZ 0.9_CD m_NN 2001_CD 1.4_CD m_NN to_TO Amersham_NNP Health_NNP ,_, and_CC 35.7_CD m_NN 2001_CD 10.3_CD m_NN to_TO Amersham_NNP Biosciences_NNP ._.
Total_JJ operating_NN profit_NN after_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN Amersham_NNP Health_NNP 254.7_CD 231.0_CD Amersham_NNP Biosciences_NNP 39.6_CD 59.5_CD Corporate_JJ and_CC other_JJ 21.1_CD 18.4_CD 273.2_CD 272.1_CD Included_VBN within_IN Amersham_NNP Health_NNP is_VBZ the_DT groups_NNS share_NN of_IN the_DT NMP_NNP joint_JJ venture_NN profit_NN before_IN interest_NN and_CC tax_NN for_IN the_DT year_NN of_IN 23.2_CD m_NN 2001_CD 26.1_CD m._FW 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Restated_VBN m_FW m_FW Net_JJ assets_NNS Amersham_NNP Health_NNP 559.9_CD 451.5_CD Amersham_NNP Biosciences_NNP 1,032.6_CD 413.2_CD Corporate_JJ and_CC other_JJ 33.7_CD 20.2_CD Net_NN operating_VBG assets_NNS 1,558.8_CD 844.5_CD Unallocated_JJ net_JJ liabilities_NNS Current_JJ and_CC deferred_JJ taxation_NN 163.6_CD 129.9_CD Dividends_NNS payable_JJ 36.0_CD 30.3_CD Net_JJ debt_NN 182.3_CD 25.4_CD 1,176.9_CD 658.9_CD The_DT net_JJ assets_NNS of_IN Amersham_NNP Biosciences_NNP include_VBP goodwill_NN at_IN a_DT net_JJ book_NN value_NN of_IN 630.6_CD m_NN at_IN 31_CD December_NNP 2002_CD arising_VBG from_IN the_DT purchase_NN of_IN the_DT 45_CD %_NN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS ._.
Included_VBN within_IN the_DT net_JJ operating_NN assets_NNS of_IN Amersham_NNP Health_NNP is_VBZ the_DT groups_NNS share_NN of_IN the_DT NMP_NNP joint_JJ venture_NN assets_NNS of_IN 73.0_CD m_NN ,_, 2001_CD 67.1_CD m._NN 58_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 2_CD Segmental_JJ analysis_NN by_IN geographical_JJ sector_NN 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD By_IN origin_NN m_NN m_NN Sales_NNS Europe_NNP 903.9_CD 722.1_CD North_NNP America_NNP 871.8_CD 853.7_CD Japan_NNP 187.8_CD 202.1_CD Asia_NNP Pacic_NNP 84.0_CD 77.5_CD Rest_VBP of_IN the_DT world_NN 5.2_CD 6.7_CD 2,052.7_CD 1,862.1_CD Less_RBR inter-segment_JJ sales_NNS 434.5_CD 259.6_CD 1,618.2_CD 1,602.5_CD Included_VBN within_IN Japan_NNP is_VBZ the_DT groups_NNS share_NN of_IN NMP_NNP joint_JJ venture_NN sales_NNS of_IN 80.5_CD m_NN 2001_CD 87.3_CD m._NN Total_JJ operating_NN profit_NN before_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN Europe_NNP 219.3_CD 193.0_CD North_NNP America_NNP 80.3_CD 89.7_CD Japan_NNP 31.9_CD 30.4_CD Asia_NNP Pacic_NNP 0.9_CD 0.3_CD Rest_VBP of_IN the_DT world_NN 0.3_CD 0.5_CD Corporate_JJ and_CC other_JJ 21.1_CD 20.8_CD 309.8_CD 292.5_CD The_DT following_VBG table_NN shows_NNS operating_VBG profit_NN after_IN allocation_NN of_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN ._.
The_DT exceptional_JJ items_NNS charged_VBN in_IN 2002_CD relate_VBP nil_NN 2001_CD 1.1_CD m_NN to_TO North_NNP America_NNP ,_, nil_NN 2001_CD 10.0_CD m_NN to_TO Europe_NNP and_CC nil_JJ 2001_CD 2.4_CD m_NN income_NN to_TO Corporate_JJ and_CC other_JJ ._.
Total_JJ operating_NN profit_NN after_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN Europe_NNP 210.4_CD 182.7_CD North_NNP America_NNP 57.6_CD 77.2_CD Japan_NNP 26.9_CD 30.4_CD Asia_NNP Pacic_NNP 0.9_CD 0.3_CD Rest_VBP of_IN the_DT world_NN 0.3_CD 0.5_CD Corporate_JJ and_CC other_JJ 21.1_CD 18.4_CD 273.2_CD 272.1_CD Included_VBN within_IN Japan_NNP is_VBZ the_DT groups_NNS share_NN of_IN NMP_NNP joint_JJ venture_NN profit_NN before_IN interest_NN and_CC tax_NN for_IN the_DT year_NN of_IN 23.2_CD m_NN 2001_CD 26.1_CD m._FW 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Restated_VBN m_FW m_FW Net_JJ assets_NNS Europe_NNP 709.3_CD 383.1_CD North_NNP America_NNP 603.0_CD 322.4_CD Japan_NNP 228.9_CD 107.8_CD Asia_NNP Pacic_NNP 49.5_CD 49.8_CD Rest_VBP of_IN the_DT world_NN 1.8_CD 1.6_CD Corporate_JJ and_CC other_JJ 33.7_CD 20.2_CD Net_NN operating_VBG assets_NNS 1,558.8_CD 844.5_CD Unallocated_JJ net_JJ liabilities_NNS Current_JJ and_CC deferred_JJ taxation_NN 163.6_CD 129.9_CD Dividends_NNS payable_JJ 36.0_CD 30.3_CD Net_JJ debt_NN 182.3_CD 25.4_CD 1,176.9_CD 658.9_CD The_DT net_JJ assets_NNS include_VBP goodwill_NN at_IN a_DT net_JJ book_NN value_NN of_IN 630.6_CD m_NN at_IN 31_CD December_NNP 2002_CD arising_VBG from_IN the_DT purchase_NN of_IN the_DT 45_CD %_NN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS ._.
The_DT goodwill_NN is_VBZ allocated_VBN to_TO Europe_NNP 207.1_CD m_NN ,_, North_NNP America_NNP 304.1_CD m_NN and_CC Japan_NNP 119.4_CD m_NN ,_, based_VBN on_IN expected_VBN revenues_NNS arising_VBG in_IN those_DT territories_NNS ._.
Included_VBN within_IN the_DT net_JJ operating_NN assets_NNS of_IN Japan_NNP is_VBZ the_DT groups_NNS share_NN of_IN the_DT NMP_NNP joint_JJ venture_NN assets_NNS of_IN 73.0_CD m_NN ,_, 2001_CD 67.1_CD m._NN Amersham_NNP plc_NN 59_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 2_CD Segmental_JJ analysis_NN by_IN geographical_JJ sector_NN continued_VBD 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD By_IN destination_NN m_NN m_NN Sales_NNS Europe_NNP 427.8_CD 392.0_CD North_NNP America_NNP 798.5_CD 767.7_CD Japan_NNP 264.1_CD 290.7_CD Asia_NNP Pacic_NNP 80.6_CD 80.4_CD Rest_VBP of_IN the_DT world_NN 47.2_CD 71.7_CD 1,618.2_CD 1,602.5_CD Included_VBN within_IN Japan_NNP is_VBZ the_DT groups_NNS share_NN of_IN NMP_NNP joint_JJ venture_NN sales_NNS during_IN the_DT year_NN of_IN 80.5_CD m_NN 2001_CD 87.3_CD m._NN 3_CD Exceptional_JJ items_NNS 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Cost_NN of_IN the_DT proposed_VBN otation_NN of_IN Amersham_NNP Biosciences_NNP 3.4_CD Transfer_NNP of_IN pension_NN assets_NNS 9.0_CD Costs_NNS of_IN exiting_VBG the_DT disease_NN proling_VBG project_NN 5.8_CD Costs_NNS of_IN exiting_VBG Harwell_NNP site_NN 8.5_CD Charged_VBN to_TO operating_VBG profit_NN 8.7_CD profit_NN on_IN disposal_NN of_IN 29_CD %_NN of_IN Nycomed_NNP Pharma_NNP 55.3_CD profit_NN on_IN sale_NN of_IN xed_JJ asset_NN investment_NN 55.3_CD Tax_NNP credit_NN relating_VBG to_TO group_NN reorganisation_NN 9.2_CD Total_JJ exceptional_JJ items_NNS 9.2_CD 46.6_CD Tax_NNP credit_NN related_VBN to_TO exceptional_JJ items_NNS 0.5_CD As_IN a_DT result_NN of_IN the_DT formation_NN of_IN a_DT consolidated_JJ tax_NN group_NN in_IN the_DT US_NNP on_IN 31_CD July_NNP 2002_CD ,_, the_DT group_NN has_VBZ recognized_VBN a_DT deferred_VBN taxation_NN asset_NN of_IN 9.2_CD m_NN primarily_RB related_VBN to_TO the_DT future_JJ utilisation_NN of_IN tax_NN losses_NNS arising_VBG from_IN prior_JJ periods_NNS ._.
During_IN 2001_CD ,_, costs_NNS of_IN 3.4_CD m_NN were_VBD incurred_VBN in_IN relation_NN to_TO the_DT proposed_VBN partial_JJ otation_NN of_IN Amersham_NNP Biosciences_NNPS ._.
The_DT costs_NNS related_VBN primarily_RB to_TO adviser_NN fees_NNS and_CC other_JJ similar_JJ costs_NNS in_IN preparing_VBG the_DT prospectus_NN for_IN otation_NN and_CC in_IN relocating_VBG the_DT business_NN to_TO the_DT US_NNP ._.
During_IN 2001_CD ,_, the_DT company_NN received_VBD 22.5_CD m_NN related_VBN to_TO a_DT transfer_NN of_IN assets_NNS from_IN former_JJ pension_NN plans_NNS ._.
Of_IN this_DT amount_NN ,_, 13.5_CD m_NN was_VBD applied_VBN against_IN ongoing_JJ liabilities_NNS primarily_RB for_IN employees_NNS who_WP have_VBP transferred_VBN into_IN Amersham_NNP pension_NN schemes_NNS and_CC the_DT balance_NN of_IN 9.0_CD m_NN was_VBD recognized_VBN as_IN exceptional_JJ income_NN ,_, where_WRB the_DT company_NN has_VBZ no_DT further_JJ liability_NN ._.
Cash_NN costs_NNS of_IN 4.1_CD m_NN and_CC non-cash_JJ write_VB offs_NNS of_IN 1.7_CD m_NN were_VBD incurred_VBN in_IN the_DT second_JJ half_NN of_IN 2001_CD in_IN concluding_VBG research_NN on_IN ,_, and_CC winding_VBG up_RP the_DT operation_NN of_IN an_DT early_JJ stage_NN investment_NN in_IN ,_, disease_NN proling_NN ._.
An_DT investment_NN of_IN 4.0_CD m_NN was_VBD made_VBN in_IN the_DT research_NN project_NN in_IN the_DT first_JJ half_NN of_IN 2001_CD ,_, which_WDT has_VBZ been_VBN charged_VBN to_TO operating_VBG activities_NNS ._.
In_IN 2001_CD ,_, costs_NNS of_IN 8.5_CD m_NN were_VBD accrued_VBN in_IN relation_NN to_TO the_DT decision_NN to_TO terminate_VB the_DT groups_NNS lease_NN at_IN the_DT Harwell_NNP site_NN following_VBG a_DT complete_JJ cessation_NN of_IN the_DT groups_NNS activities_NNS at_IN this_DT location_NN ._.
The_DT costs_NNS relate_VBP primarily_RB to_TO asset_NN write_VB offs_NNS and_CC decommissioning_VBG costs_NNS ._.
During_IN 2001_CD ,_, the_DT group_NN sold_VBD its_PRP$ 29_CD %_NN interest_NN in_IN Nycomed_NNP Pharma_NNP ._.
The_DT group_NN recorded_VBD a_DT profit_NN on_IN the_DT transaction_NN of_IN 55.3_CD m_NN after_IN charging_VBG costs_NNS associated_VBN with_IN the_DT disposal_NN ._.
In_IN 2001_CD ,_, the_DT minority_NN impact_NN was_VBD 2.0_CD m_NN relating_VBG to_TO exceptional_JJ items_NNS charged_VBN to_TO operating_VBG profit_NN ._.
In_IN 2002_CD ,_, no_DT exceptional_JJ items_NNS have_VBP been_VBN charged_VBN to_TO operating_VBG profit_NN ._.
60_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 4_CD Total_JJ operating_NN profit_NN 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 12_CD months_NNS to_TO 31_CD Dec_NNP 2001_CD Before_IN Before_IN exceptional_JJ Exceptional_JJ exceptional_JJ Exceptional_JJ items_NNS items_NNS Total_JJ items_NNS items_NNS Total_JJ m_NN m_FW m_FW m_FW m_FW m_FW Group_NNP turnover_NN 1,537.7_CD 1,537.7_CD 1,515.2_CD 1,515.2_CD Cost_NN of_IN sales_NNS 481.0_CD 481.0_CD 500.1_CD 0.5_CD 499.6_CD Gross_NNP profit_NN 1,056.7_CD 1,056.7_CD 1,015.1_CD 0.5_CD 1,015.6_CD Distribution_NN and_CC selling_NN costs_NNS 419.7_CD 419.7_CD 401.8_CD 401.8_CD Administrative_JJ expenses_NNS 387.0_CD 387.0_CD 358.6_CD 9.2_CD 367.8_CD Group_NNP operating_NN profit_NN 250.0_CD 250.0_CD 254.7_CD 8.7_CD 246.0_CD Share_NN of_IN operating_VBG profits_NNS of_IN joint_JJ venture_NN and_CC associates_NNS 23.2_CD 23.2_CD 26.1_CD 26.1_CD Total_JJ operating_NN profit_NN 273.2_CD 273.2_CD 280.8_CD 8.7_CD 272.1_CD Research_NNP and_CC development_NN costs_NNS included_VBD in_IN administrative_JJ expenses_NNS relate_VBP to_TO Amersham_NNP Health_NNP 95.1_CD m_NN 2001_CD 83.0_CD m_NN ,_, Amersham_NNP Biosciences_NNP 88.0_CD m_NN 2001_CD 86.4_CD m_NN ,_, and_CC Corporate_JJ and_CC other_JJ 1.1_CD m_NN 2001_CD 4.4_CD m._NN Total_JJ research_NN and_CC development_NN costs_NNS amounted_VBD to_TO 184.2_CD m_NN 2001_CD 173.8_CD m._FW Goodwill_NNP amortisation_NN charged_VBD to_TO administrative_JJ expenses_NNS in_IN 2002_CD is_VBZ 36.6_CD m_NN 2001_CD 11.7_CD m._FW 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Total_JJ operating_NN profit_NN is_VBZ arrived_VBN at_IN after_IN charging_VBG :_: Remuneration_NNP of_IN the_DT groups_NNS auditors_NNS Audit_NNP fees_NNS company_NN 0.1_CD m_NN :_: 2001_CD 0.1_CD m_NN 1.6_CD 1.3_CD Other_JJ services_NNS to_TO the_DT group_NN in_IN the_DT UK_NNP 0.1_CD 0.2_CD in_IN the_DT rest_NN of_IN the_DT world_NN primarily_RB related_VBN to_TO taxation_NN 0.4_CD 0.2_CD Operating_NN lease_NN rentals_NNS Hire_VBP of_IN plant_NN and_CC machinery_NN 14.5_CD 13.9_CD Hire_NNP of_IN land_NN and_CC buildings_NNS and_CC other_JJ xed_JJ assets_NNS 15.1_CD 14.3_CD Amortisation_NNP of_IN government_NN grants_NNS 0.2_CD 0.2_CD Depreciation_NN of_IN tangible_JJ xed_JJ assets_NNS Owned_VBN 72.0_CD 61.1_CD Held_VBN under_IN finance_NN leases_VBZ 0.3_CD 0.4_CD Amortisation_NNP of_IN intangible_JJ xed_JJ assets_NNS Goodwill_NNP 36.6_CD 11.7_CD Other_JJ intangibles_NNS 7.7_CD 6.8_CD Loss_NN on_IN disposal_NN of_IN tangible_JJ xed_JJ assets_NNS 1.5_CD 0.3_CD 5_CD Directors_NNS emoluments_VBZ 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Basic_JJ salary_NN 2.2_CD 1.4_CD Fees_NNS 0.5_CD 0.4_CD Benets_NNP 0.4_CD 0.3_CD Annual_JJ bonuses_NNS 1.2_CD 1.1_CD Payments_NNS of_IN pension_NN contributions_NNS 0.2_CD 0.2_CD Compensation_NNP for_IN loss_NN of_IN ofce_NN 0.8_CD Payments_NNS to_TO past_JJ Directors_NNS 0.4_CD 0.4_CD 5.7_CD 3.8_CD Gains_NNS made_VBN on_IN exercise_NN of_IN share_NN options_NNS and_CC long_JJ term_NN incentive_NN shares_NNS 1.4_CD 5.7_CD 5.2_CD Detailed_JJ disclosures_NNS of_IN Directors_NNS individual_JJ remuneration_NN ,_, pension_NN entitlements_NNS ,_, share_NN options_NNS and_CC long_JJ term_NN incentives_NNS are_VBP given_VBN in_IN the_DT Remuneration_NNP report_NN on_IN pages_NNS 43_CD to_TO 50_CD ._.
Amersham_NNP plc_NN 61_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 6_CD Employee_NN information_NN The_DT weighted_JJ average_JJ number_NN of_IN persons_NNS including_VBG Executive_NNP Directors_NNS employed_VBN by_IN the_DT group_NN during_IN the_DT year_NN is_VBZ analyzed_VBN by_IN type_NN of_IN work_NN below_IN ._.
12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Number_NNP Number_NNP Production_NNP and_CC development_NN 4,962_CD 4,587_CD Distribution_NN and_CC selling_VBG 3,262_CD 3,140_CD Administration_NNP 1,827_CD 1,792_CD 10,051_CD 9,519_CD 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Staff_NN costs_NNS Aggregate_JJ gross_JJ wages_NNS and_CC salaries_NNS 376.2_CD 337.3_CD Employers_NNS National_NNP Insurance_NNP contributions_NNS or_CC foreign_JJ equivalents_NNS 72.5_CD 55.3_CD Employers_NNS pension_NN costs_NNS under_IN group_NN pension_NN schemes_NNS 27.1_CD 20.9_CD Total_JJ direct_JJ costs_NNS of_IN employment_NN 475.8_CD 413.5_CD 7_CD Net_JJ interest_NN payable_JJ 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Interest_NN payable_JJ and_CC similar_JJ charges_NNS On_IN bank_NN loans_NNS and_CC overdrafts_NNS 1.9_CD 3.5_CD On_IN other_JJ loans_NNS 6.9_CD 13.3_CD Unwinding_NN of_IN discount_NN on_IN decommissioning_VBG provision_NN 2.8_CD 2.1_CD 11.6_CD 18.9_CD Interest_NN receivable_NN and_CC similar_JJ income_NN Interest_NN on_IN short_JJ term_NN deposits_NNS and_CC interest_NN bearing_NN investments_NNS 4.5_CD 10.2_CD Net_JJ interest_NN payable_JJ 7.1_CD 8.7_CD Included_VBN within_IN interest_NN payable_JJ and_CC similar_JJ charges_NNS ,_, relating_VBG to_TO the_DT unwinding_VBG of_IN the_DT discount_NN on_IN the_DT decommissioning_VBG provision_NN ,_, is_VBZ 0.6_CD m_NN 2001_CD 0.6_CD m_NN attributable_JJ to_TO the_DT groups_NNS joint_JJ venture_NN in_IN NMP_NNP ._.
8_CD Tax_NN on_IN profit_NN on_IN ordinary_JJ activities_NNS 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Restated_NNP Note_NN m_NN m_NN UK_NNP corporation_NN tax_NN at_IN 30_CD %_NN 2001_CD 30_CD %_NN Current_JJ 4.0_CD 23.0_CD Double_RB tax_NN relief_NN 8.2_CD 15.4_CD 4.2_CD 7.6_CD Overseas_JJ taxation_NN 83.9_CD 69.3_CD Over-provision_NN in_IN respect_NN of_IN prior_JJ years_NNS 18.6_CD 0.6_CD Share_NN of_IN joint_JJ venture_NN and_CC associates_NNS 10.1_CD 11.7_CD Total_JJ current_JJ tax_NN 71.2_CD 88.0_CD Deferred_JJ tax_NN Origination_NNP and_CC reversal_NN of_IN timing_NN differences_NNS 7.1_CD 13.8_CD Prior_RB year_NN deferred_VBN tax_NN movement_NN 16.0_CD 4.8_CD Total_JJ deferred_JJ tax_NN 23.1_CD 9.0_CD Tax_NNP before_IN exceptional_JJ items_NNS 94.3_CD 97.0_CD Exceptional_JJ items_NNS 3_CD 9.2_CD 0.5_CD 85.1_CD 96.5_CD The_DT groups_NNS tax_NN charge_NN has_VBZ benefited_VBN from_IN a_DT net_JJ over-provision_NN in_IN respect_NN of_IN prior_JJ years_NNS of_IN 2.6_CD m_NN net_JJ movement_NN between_IN current_JJ and_CC deferred_JJ tax_NN ._.
This_DT is_VBZ principally_RB as_IN a_DT result_NN of_IN the_DT favourable_JJ settlement_NN of_IN earlier_JJR years_NNS taxation_NN issues_NNS ._.
Furthermore_RB ,_, as_IN a_DT result_NN of_IN the_DT purchase_NN of_IN the_DT 45_CD %_NN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS in_IN the_DT year_NN and_CC the_DT subsequent_JJ formation_NN of_IN a_DT US_NNP consolidated_JJ tax_NN group_NN ,_, it_PRP has_VBZ been_VBN possible_JJ to_TO recognize_VB certain_JJ tax_NN losses_NNS in_IN the_DT US_NNP ._.
The_DT deferred_JJ tax_NN benefit_NN arising_VBG has_VBZ been_VBN treated_VBN as_IN an_DT exceptional_JJ item_NN ._.
62_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 8_CD Tax_NN on_IN profit_NN on_IN ordinary_JJ activities_NNS continued_VBD The_DT current_JJ tax_NN charge_NN for_IN the_DT period_NN is_VBZ lower_JJR 2001_CD higher_JJR than_IN the_DT standard_JJ rate_NN of_IN corporation_NN tax_NN in_IN the_DT UK_NNP of_IN 30_CD %_NN ._.
The_DT differences_NNS are_VBP explained_VBN below_IN :_: 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Restated_VBN m_NN m_NN profit_NN on_IN ordinary_JJ activities_NNS before_IN tax_NN before_IN exceptional_JJ items_NNS 263.7_CD 267.7_CD profit_NN on_IN ordinary_JJ activities_NNS multiplied_VBN by_IN the_DT standard_JJ rate_NN of_IN corporation_NN tax_NN in_IN the_DT UK_NNP of_IN 30_CD %_NN 2001_CD :_: 30_CD %_NN 79.1_CD 80.3_CD Effects_NNPS of_IN :_: Adjustments_NNS in_IN respect_NN of_IN prior_JJ period_NN 18.6_CD 0.6_CD Adjustments_NNS in_IN respect_NN of_IN foreign_JJ tax_NN rates_NNS 7.4_CD 4.6_CD Expenses_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS :_: Non_NNP tax_NN deductible_JJ goodwill_NN 11.7_CD 5.1_CD Other_JJ 1.7_CD 0.8_CD Timing_NN differences_NNS :_: Capital_NNP allowances_NNS in_IN excess_NN of_IN depreciation_NN 8.0_CD 0.8_CD Tax_NNP deductible_JJ goodwill_NN 3.8_CD 3.8_CD Unrealised_JJ stock_NN profit_NN 4.8_CD 0.1_CD Research_NNP and_CC development_NN credits_NNS 3.9_CD 3.9_CD Unutilised_JJ tax_NN losses_NNS 0.8_CD 6.4_CD 71.2_CD 88.0_CD Exceptional_JJ items_NNS 0.5_CD 71.2_CD 87.5_CD 9_CD Dividends_NNS paid_VBN and_CC proposed_VBN 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Paid_VBD interim_JJ dividend_NN of_IN 2.65_CD p_NN per_IN share_NN 2001_CD 2.35_CD p_NN per_IN share_NN 21.3_CD 14.9_CD Proposed_VBN final_JJ dividend_NN of_IN 5.15_CD p_NN per_IN share_NN 2001_CD 4.75_CD p_NN per_IN share_NN 36.0_CD 30.3_CD 57.3_CD 45.2_CD Dividends_NNS paid_VBN of_IN 21.3_CD m_NN contains_VBZ 2.9_CD m_NN relating_VBG to_TO the_DT final_JJ 2001_CD dividend_NN paid_VBN to_TO holders_NNS of_IN the_DT 57.5_CD m_NN new_JJ ordinary_JJ shares_NNS which_WDT were_VBD issued_VBN by_IN means_NNS of_IN a_DT placing_NN on_IN 18_CD March_NNP 2002_CD ._.
A_DT final_JJ dividend_NN of_IN 5.15_CD p_NN per_IN share_NN is_VBZ proposed_VBN ,_, bringing_VBG the_DT total_JJ dividend_NN for_IN the_DT year_NN to_TO 7.80_CD p._NN 10_CD Earnings_NNS per_IN ordinary_JJ share_NN Basic_JJ earnings_NNS per_IN ordinary_JJ share_NN is_VBZ calculated_VBN by_IN dividing_VBG the_DT earnings_NNS attributable_JJ to_TO ordinary_JJ shareholders_NNS by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS in_IN issue_NN in_IN the_DT year_NN ,_, excluding_VBG those_DT held_VBN by_IN employee_NN share_NN trusts_NNS ._.
For_IN diluted_VBN earnings_NNS per_IN ordinary_JJ share_NN ,_, the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS is_VBZ adjusted_VBN to_TO assume_VB conversion_NN of_IN all_DT potentially_RB dilutive_JJ ordinary_JJ shares_NNS ._.
Amersham_NNP plc_NN 63_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 10_CD Earnings_NNS per_IN ordinary_JJ share_NN continued_VBN The_DT calculation_NN of_IN earnings_NNS per_IN ordinary_JJ share_NN is_VBZ based_VBN on_IN the_DT following_VBG attributable_JJ profit_NN and_CC weighted_JJ average_JJ number_NN of_IN shares_NNS ._.
12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Restated_VBN m_FW p_FW m_FW p_FW Attributable_JJ profit_NN profit_NN attributable_JJ to_TO shareholders_NNS basic_JJ 178.7_CD 26.1_CD 210.7_CD 33.2_CD Add_VB back_RP the_DT following_VBG items_NNS Exceptional_JJ items_NNS 46.6_CD 7.3_CD Goodwill_NNP amortisation_NN 36.6_CD 5.3_CD 11.7_CD 1.9_CD Adjust_VB for_IN related_JJ amounts_NNS of_IN Taxation_NNP 9.2_CD 1.3_CD 0.5_CD 0.1_CD Minority_NNP interest_NN 1.3_CD 0.2_CD 6.7_CD 1.1_CD profit_NN attributable_JJ to_TO shareholders_NNS before_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN 204.8_CD 29.9_CD 168.6_CD 26.6_CD Average_JJ number_NN of_IN ordinary_JJ shares_NNS Basic_JJ 684.7_CD m_NN 634.4_CD m_NN Dilution_NN effect_NN of_IN outstanding_JJ share_NN options_NNS 4.0_CD m_NN 4.3_CD m_NN Diluted_NNP 688.7_CD m_NN 638.7_CD m_NN Earnings_NNS per_IN ordinary_JJ share_NN basic_JJ 26.1_CD p_NN 33.2_CD p_NN before_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN 29.9_CD p_VBP 26.6_CD p_JJ diluted_VBN after_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN 25.9_CD p_VBP 33.0_CD p_JJ Earnings_NNS per_IN ordinary_JJ share_NN before_IN exceptional_JJ items_NNS and_CC goodwill_NN amortisation_NN is_VBZ presented_VBN in_IN order_NN to_TO show_VB the_DT impact_NN on_IN earnings_NNS of_IN non-recurring_JJ items_NNS and_CC goodwill_NN ._.
11_CD Intangible_NNP xed_VBD assets_NNS Group_NNP Company_NNP Other_JJ Other_JJ Goodwill_NNP intangibles_VBZ Total_JJ intangibles_NNS m_VBP m_FW m_FW m_FW Cost_NN At_IN 1_CD January_NNP 2002_CD 146.9_CD 73.0_CD 219.9_CD 1.8_CD Foreign_JJ currency_NN translation_NN 54.6_CD 11.5_CD 43.1_CD Acquisition_NNP of_IN subsidiaries_NNS 3.9_CD 3.9_CD Goodwill_NNP subsumed_VBN on_IN purchase_NN of_IN 45_CD %_NN minority_NN in_IN Amersham_NNP Biosciences_NNP 79.3_CD 79.3_CD Additions_NNS 744.5_CD 6.4_CD 750.9_CD Disposals_NNS 6.3_CD 6.3_CD At_IN 31_CD December_NNP 2002_CD 757.5_CD 88.5_CD 846.0_CD 1.8_CD Amortisation_NNP At_IN 1_CD January_NNP 2002_CD 35.3_CD 31.9_CD 67.2_CD 1.0_CD Foreign_JJ currency_NN translation_NN 3.2_CD 6.4_CD 3.2_CD Amortisation_NNP subsumed_VBN on_IN purchase_NN of_IN 45_CD %_NN minority_NN in_IN Amersham_NNP Biosciences_NNP 15.4_CD 15.4_CD Disposals_NNS 4.5_CD 4.5_CD Charge_NNP for_IN the_DT year_NN 36.6_CD 7.7_CD 44.3_CD 0.2_CD At_IN 31_CD December_NNP 2002_CD 53.3_CD 41.5_CD 94.8_CD 1.2_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2002_CD 704.2_CD 47.0_CD 751.2_CD 0.6_CD At_IN 31_CD December_NNP 2001_CD 111.6_CD 41.1_CD 152.7_CD 0.8_CD Additions_NNS to_TO goodwill_NN during_IN the_DT year_NN amounted_VBD to_TO 744.5_CD m_NN :_: 692.3_CD m_NN arose_VBD on_IN the_DT purchase_NN of_IN the_DT 45_CD %_NN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNP ,_, including_VBG 45_CD %_NN of_IN Amersham_NNP Biosciences_NNP goodwill_NN of_IN 63.9_CD m_NN ,_, and_CC 52.2_CD m_NN arose_VBD on_IN other_JJ acquisitions_NNS ,_, see_VBP note_NN 24_CD ._.
Additions_NNS to_TO other_JJ intangibles_NNS of_IN 6.4_CD m_NN during_IN the_DT year_NN comprise_VBP a_DT number_NN of_IN license_NN agreements_NNS entered_VBD into_IN by_IN the_DT group_NN ._.
Included_VBN in_IN the_DT cost_NN of_IN land_NN and_CC buildings_NNS is_VBZ 3.2_CD m_NN 2001_CD 3.0_CD m_NN ,_, plant_NN and_CC machinery_NN nil_NN 2001_CD nil_NN ,_, and_CC xtures_NNS ,_, ttings_NNS ,_, tools_NNS and_CC equipment_NN 0.8_CD m_NN 2001_CD 0.8_CD m_NN ,_, in_IN respect_NN of_IN assets_NNS held_VBN under_IN finance_NN leases_NNS for_IN the_DT group_NN ,_, and_CC nil_NN 2001_CD nil_NN for_IN the_DT company_NN ._.
Depreciation_NN on_IN assets_NNS held_VBN under_IN finance_NN leases_NNS during_IN the_DT year_NN amounted_VBD to_TO 0.3_CD m_NN 2001_CD 0.4_CD m._FW Included_VBN in_IN the_DT net_JJ book_NN value_NN of_IN land_NN and_CC buildings_NNS is_VBZ 2.2_CD m_NN 2001_CD 2.3_CD m_NN ,_, plant_NN and_CC machinery_NN nil_NN ,_, 2001_CD nil_NN and_CC xtures_NNS ,_, ttings_NNS ,_, tools_NNS and_CC equipment_NN 0.3_CD m_NN 2001_CD 0.5_CD m_NN ,_, in_IN respect_NN of_IN assets_NNS held_VBN under_IN finance_NN leases_NNS for_IN the_DT group_NN ,_, and_CC nil_NN 2001_CD nil_NN for_IN the_DT company_NN ._.
The_DT 0.9_CD m_NN transferred_VBN to_TO current_JJ assets_NNS relates_VBZ to_TO demonstration_NN equipment_NN reclassied_VBD to_TO within_IN nished_VBN goods_NNS stock_NN ._.
Amersham_NNP plc_NN 65_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 13_CD Fixed_VBN asset_NN investments_NNS Investment_NN in_IN own_JJ Joint_NNP Trade_NNP shares_NNS venture_NN Associates_NNPS investments_NNS Total_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW Cost_NN or_CC valuation_NN At_IN 1_CD January_NNP 2002_CD 21.3_CD 67.1_CD 3.7_CD 19.4_CD 111.5_CD Foreign_JJ currency_NN translation_NN 0.9_CD 0.6_CD 0.9_CD 2.4_CD Transfer_NNP to_TO subsidiary_NN 2.6_CD 2.6_CD Fair_NNP value_NN adjustments_NNS relating_VBG to_TO the_DT purchase_NN of_IN Amersham_NNP Biosciences_NNP 1.2_CD 1.2_CD Additions_NNS 1.8_CD 3.4_CD 5.2_CD Disposals_NNS 5.3_CD 5.3_CD Transfer_NNP to_TO employees_NNS 3.9_CD 3.9_CD Share_NN of_IN retained_VBN profit_NN 6.5_CD 6.5_CD At_IN 31_CD December_NNP 2002_CD 18.3_CD 73.0_CD 3.7_CD 12.8_CD 107.8_CD Provision_NNP At_IN 1_CD January_NNP 2002_CD 1.5_CD 2.7_CD 5.2_CD 9.4_CD Foreign_JJ currency_NN translation_NN 0.2_CD 0.2_CD Charge_NNP to_TO profit_VB and_CC loss_NN 0.4_CD 1.0_CD 1.0_CD 2.4_CD Disposals_NNS 3.2_CD 3.2_CD At_IN 31_CD December_NNP 2002_CD 1.9_CD 3.7_CD 2.8_CD 8.4_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2002_CD 16.4_CD 73.0_CD 10.0_CD 99.4_CD At_IN 31_CD December_NNP 2001_CD 19.8_CD 67.1_CD 1.0_CD 14.2_CD 102.1_CD Investment_NN in_IN own_JJ shares_NNS group_NN and_CC company_NN Investment_NN in_IN own_JJ shares_NNS is_VBZ held_VBN through_IN a_DT Qualifying_VBG Employee_NN Share_NN Ownership_NNP Trust_NNP QUEST_NNP ,_, through_IN the_DT Amersham_NNP ESOP_NNP Trust_NNP A_NNP ESOP_NNP ,_, and_CC by_IN the_DT Amersham_NNP US_NNP Stock_NNP Option_NN Plan_NNP Trust_NNP 2000_CD ._.
Shares_NNS held_VBN by_IN the_DT QUEST_NNP are_VBP issued_VBN by_IN the_DT company_NN and_CC held_VBN on_IN trust_NN for_IN employees_NNS ._.
The_DT shares_NNS are_VBP transferred_VBN to_TO employees_NNS on_IN the_DT exercise_NN of_IN options_NNS under_IN an_DT authorised_JJ Save_NNP As_IN You_PRP Earn_VBP Scheme_NNP SAYE_NNP ._.
Shares_NNS held_VBN by_IN A_DT ESOP_NNP and_CC the_DT Amersham_NNP US_NNP Stock_NNP Option_NN Plan_NNP Trust_NNP 2000_CD are_VBP purchased_VBN in_IN the_DT market_NN using_VBG funds_NNS advanced_VBN by_IN the_DT company_NN and_CC are_VBP held_VBN on_IN trust_NN for_IN the_DT employees_NNS eligible_JJ under_IN the_DT companys_NNS long_JJ term_NN incentive_NN plan_NN ,_, cash_NN options_NNS under_IN the_DT Amersham_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP 1993_CD and_CC options_NNS under_IN the_DT Amersham_NNP US_NNP Stock_NNP Option_NN Plan_NN 2000_CD ._.
The_DT cost_NN of_IN the_DT funds_NNS advanced_VBD to_TO A_DT ESOP_NNP that_WDT relate_VBP to_TO the_DT companys_NNS long_JJ term_NN incentive_NN plans_VBZ LTIP_NNP is_VBZ amortised_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT three_CD year_NN life_NN of_IN the_DT scheme_NN ._.
770,057_CD shares_NNS are_VBP held_VBN by_IN the_DT QUEST_NNP ,_, with_IN a_DT market_NN value_NN at_IN 31_CD December_NNP 2002_CD of_IN 4.3_CD m_NN and_CC a_DT nominal_JJ value_NN of_IN 0.04_CD m._FW 545,282_CD shares_NNS are_VBP held_VBN by_IN the_DT A_NNP ESOP_NNP ,_, with_IN a_DT market_NN valuation_NN at_IN 31_CD December_NNP 2002_CD of_IN 3.0_CD m_NN and_CC a_DT nominal_JJ value_NN of_IN 0.03_CD m._FW 2,251,315_CD shares_NNS are_VBP held_VBN by_IN the_DT Amersham_NNP US_NNP Stock_NNP Option_NN Plan_NNP Trust_NNP 2000_CD with_IN a_DT market_NN valuation_NN at_IN 31_CD December_NNP 2002_CD of_IN 12.5_CD m_NN and_CC a_DT nominal_JJ value_NN of_IN 0.1_CD m._FW Dividends_NNPS have_VBP been_VBN partially_RB waived_VBN for_IN all_DT schemes_NNS ._.
100_CD %_NN of_IN the_DT shares_NNS held_VBN by_IN the_DT A_NNP ESOP_NNP and_CC the_DT Amersham_NNP US_NNP Stock_NNP Option_NN Plan_NNP Trust_NNP 2000_CD are_VBP under_IN option_NN to_TO employees_NNS ._.
None_NN of_IN the_DT QUEST_NNP shares_NNS are_VBP under_IN option_NN to_TO employees_NNS ._.
Transfer_NN to_TO subsidiary_NN The_DT 2.6_CD m_NN transfer_NN to_TO subsidiary_NN relates_VBZ to_TO the_DT existing_VBG trade_NN investment_NN in_IN Cimarron_NNP Software_NNP Inc_NNP ,_, which_WDT became_VBD a_DT subsidiary_NN undertaking_NN in_IN the_DT year_NN ._.
Market_NN value_NN of_IN listed_VBN investments_NNS The_DT market_NN value_NN of_IN listed_VBN investments_NNS at_IN 31_CD December_NNP 2002_CD is_VBZ 3.6_CD m_NN ,_, 2001_CD 4.9_CD m_NN ,_, and_CC the_DT carrying_VBG value_NN after_IN provisions_NNS is_VBZ 5.5_CD m_NN ,_, 2001_CD 6.3_CD m._NN 66_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 13_CD Fixed_VBN asset_NN investments_NNS continued_VBD Investments_NNP Investments_NNP in_IN own_JJ in_IN group_NN shares_NNS undertakings_NNS Total_JJ Company_NN Note_NN m_FW m_FW m_FW Cost_NN or_CC valuation_NN At_IN 1_CD January_NNP 2002_CD 5.1_CD 204.1_CD 209.2_CD Foreign_JJ currency_NN translation_NN 27.2_CD 27.2_CD Revaluation_NNP of_IN investments_NNS 26_CD 3.6_CD 3.6_CD Additions_NNS 0.5_CD 1,260.8_CD 1,261.3_CD Disposals_NNS 559.4_CD 559.4_CD Transfer_NNP to_TO employees_NNS 1.5_CD 1.5_CD At_IN 31_CD December_NNP 2002_CD 4.1_CD 881.9_CD 886.0_CD Provision_NNP At_IN 1_CD January_NNP 2002_CD 1.2_CD 1.2_CD Charge_NNP to_TO profit_VB and_CC loss_NN 0.4_CD 0.4_CD At_IN 31_CD December_NNP 2002_CD 1.6_CD 1.6_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2002_CD 2.5_CD 881.9_CD 884.4_CD At_IN 31_CD December_NNP 2001_CD 3.9_CD 204.1_CD 208.0_CD Additions_NNS in_IN the_DT company_NN primarily_RB relate_VBP to_TO the_DT 708.6_CD m_NN purchase_NN of_IN the_DT 45_CD %_NN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS ._.
Following_VBG the_DT purchase_NN ,_, the_DT group_NN undertook_VBD a_DT reorganisation_NN which_WDT involved_VBD the_DT acquisition_NN and_CC disposal_NN of_IN shares_NNS between_IN the_DT company_NN and_CC its_PRP$ subsidiaries_NNS ._.
14_CD Stocks_NNS 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP m_FW m_FW m_FW m_FW Raw_FW materials_NNS and_CC consumables_NNS 53.0_CD 46.5_CD 6.9_CD 7.9_CD Work_NN in_IN progress_NN 56.7_CD 45.5_CD 6.9_CD 7.6_CD Finished_VBN goods_NNS and_CC goods_NNS for_IN resale_NN 98.3_CD 88.6_CD 4.0_CD 1.9_CD 208.0_CD 180.6_CD 17.8_CD 17.4_CD The_DT replacement_NN cost_NN of_IN stocks_NNS is_VBZ not_RB materially_RB different_JJ from_IN original_JJ cost_NN ._.
15_CD Debtors_NNS amounts_NNS due_JJ within_IN one_CD year_NN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP Restated_NNP m_FW m_FW m_FW m_FW Trade_NNP debtors_NNS 301.7_CD 298.2_CD 8.2_CD 7.9_CD Amounts_NNS owed_VBN by_IN group_NN undertakings_NNS 535.4_CD 555.6_CD Amounts_NNS owed_VBN by_IN joint_JJ venture_NN and_CC associates_NNS 1.0_CD 1.3_CD 1.0_CD 1.3_CD Other_JJ debtors_NNS 21.2_CD 34.7_CD 4.2_CD 6.7_CD Prepayments_NNS and_CC accrued_VBN income_NN 25.3_CD 26.6_CD 4.2_CD 4.9_CD 349.2_CD 360.8_CD 553.0_CD 576.4_CD 16_CD Debtors_NNS amounts_NNS due_RB after_IN one_CD year_NN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP Restated_NNP m_FW m_FW m_FW m_FW Amounts_NNPS owed_VBN by_IN group_NN undertakings_NNS 201.9_CD Other_JJ debtors_NNS 17.3_CD 16.7_CD 2.9_CD Prepayments_NNS and_CC accrued_VBN income_NN 11.1_CD 8.7_CD 10.7_CD 8.7_CD Deferred_JJ taxation_NN assets_NNS 32.9_CD 30.0_CD 61.3_CD 55.4_CD 212.6_CD 11.6_CD Amersham_NNP plc_NN 67_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 17_CD Short_JJ term_NN deposits_NNS and_CC investments_NNS 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP m_FW m_FW m_FW m_FW Short_JJ term_NN deposits_NNS included_VBD in_IN net_JJ debt_NN see_VBP note_NN 32_CD 22.1_CD 96.5_CD 21.6_CD 92.5_CD Loan_NN notes_VBZ 2.9_CD 2.9_CD 22.1_CD 99.4_CD 21.6_CD 95.4_CD 18_CD Creditors_NNS amounts_NNS due_JJ within_IN one_CD year_NN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP m_FW m_FW m_FW m_FW Loans_NNPS Short_NNP term_NN loans_NNS from_IN group_NN undertakings_NNS 857.6_CD 532.5_CD Short_JJ term_NN loan_NN from_IN joint_JJ venture_NN and_CC associates_NNS 26.2_CD 26.2_CD Bank_NNP loans_NNS and_CC overdrafts_NNS 16.2_CD 14.8_CD 0.9_CD 4.4_CD Finance_NNP lease_NN obligations_NNS 0.3_CD 0.3_CD Unsecured_JJ loan_NN notes_VBZ 1.9_CD 15.7_CD 13.8_CD 44.6_CD 30.8_CD 884.7_CD 550.7_CD Other_JJ creditors_NNS Trade_NNP creditors_NNS 71.2_CD 86.4_CD 11.5_CD 13.9_CD Amounts_NNS owed_VBN to_TO group_NN undertakings_NNS 18.2_CD 15.8_CD Amounts_NNS owed_VBN to_TO joint_JJ venture_NN and_CC associates_NNS 0.1_CD 0.1_CD 0.1_CD 0.1_CD United_NNP Kingdom_NNP corporation_NN tax_NN 6.1_CD 9.9_CD 4.8_CD 9.9_CD Overseas_JJ subsidiary_NN taxation_NN 128.9_CD 108.1_CD Other_JJ taxes_NNS and_CC social_JJ security_NN 27.0_CD 19.7_CD 2.6_CD 2.1_CD Other_JJ creditors_NNS 63.0_CD 42.9_CD 9.8_CD 6.4_CD Accruals_NNP and_CC deferred_JJ income_NN 149.9_CD 155.1_CD 51.2_CD 47.6_CD Dividends_NNS payable_JJ 36.0_CD 30.3_CD 36.0_CD 30.3_CD 482.2_CD 452.5_CD 134.2_CD 126.1_CD 526.8_CD 483.3_CD 1,018.9_CD 676.8_CD 19_CD Creditors_NNS amounts_NNS due_RB after_IN one_CD year_NN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP m_FW m_FW m_FW m_FW Loans_NNPS Bank_NNP loans_NNS and_CC overdrafts_NNS 68.5_CD 8.7_CD 61.6_CD Finance_NNP lease_NN obligations_NNS 2.5_CD 2.7_CD Unsecured_JJ loan_NN notes_NNS 121.5_CD 136.6_CD 119.9_CD 133.1_CD 192.5_CD 148.0_CD 181.5_CD 133.1_CD Other_JJ creditors_NNS 11.5_CD 6.4_CD 3.7_CD 6.7_CD 204.0_CD 154.4_CD 185.2_CD 139.8_CD Repayments_NNS are_VBP due_JJ as_IN follows_VBZ :_: Between_IN one_CD and_CC two_CD years_NNS 108.6_CD 7.9_CD 103.9_CD 3.0_CD Between_IN two_CD and_CC five_CD years_NNS 84.3_CD 134.3_CD 71.6_CD 125.8_CD In_IN five_CD years_NNS or_CC more_JJR 11.1_CD 12.2_CD 9.7_CD 11.0_CD 204.0_CD 154.4_CD 185.2_CD 139.8_CD The_DT company_NN has_VBZ $_$ 193.0_CD m_NN ,_, 2001_CD $_$ 213.0_CD m_NN ,_, equivalent_JJ to_TO 123.4_CD m_NN ,_, 2001_CD 152.3_CD m_NN ,_, of_IN private_JJ placement_NN unsecured_JJ loan_NN notes_NNS see_VBP note_NN 20_CD ._.
The_DT carrying_VBG value_NN of_IN these_DT notes_NNS includes_VBZ a_DT fair_JJ value_NN adjustment_NN of_IN 3.5_CD m_NN ,_, 2001_CD 5.4_CD m._NN The_DT fair_JJ value_NN adjustment_NN arose_VBD on_IN the_DT acquisition_NN of_IN the_DT notes_NNS at_IN the_DT time_NN of_IN the_DT merger_NN with_IN Nycomed_NNP ._.
Of_IN the_DT carrying_VBG value_NN ,_, 1.9_CD m_NN ,_, 2001_CD 15.7_CD m_NN ,_, is_VBZ reported_VBN in_IN amounts_NNS due_JJ within_IN one_CD year_NN ._.
68_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 20_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS A_DT discussion_NN of_IN the_DT groups_NNS objectives_NNS and_CC policies_NNS with_IN regard_NN to_TO the_DT use_NN of_IN financial_JJ instruments_NNS is_VBZ found_VBN in_IN the_DT Treasury_NNP Policy_NN and_CC Liquidity_NN section_NN of_IN the_DT Financial_NNP review_NN on_IN page_NN 33_CD ._.
Where_WRB permitted_VBN by_IN FRS13_CD ,_, disclosures_NNS in_IN this_DT note_NN exclude_VBP short_JJ term_NN debtors_NNS and_CC creditors_NNS ._.
a_DT Currency_NN and_CC interest_NN rate_NN composition_NN of_IN financial_JJ liabilities_NNS of_IN the_DT group_NN The_DT following_VBG table_NN analyses_VBZ the_DT currency_NN and_CC interest_NN rate_NN composition_NN of_IN the_DT groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP after_IN taking_VBG into_IN account_NN interest_NN rate_NN and_CC currency_NN swaps_NNS ._.
The_DT financial_JJ liabilities_NNS comprise_VBP bank_NN loans_NNS and_CC overdrafts_NNS plus_CC any_DT long_JJ term_NN contractual_JJ obligations_NNS to_TO deliver_VB cash_NN or_CC other_JJ financial_JJ assets_NNS to_TO third_JJ parties_NNS ._.
In_IN addition_NN a_DT short_JJ term_NN loan_NN from_IN the_DT groups_NNS joint_JJ venture_NN of_IN 26.2_CD m_NN 2001_CD nil_NN is_VBZ included_VBN within_IN the_DT analysis_NN of_IN net_JJ debt_NN ._.
The_DT average_JJ interest_NN rates_NNS for_IN the_DT financial_JJ liabilities_NNS of_IN the_DT group_NN at_IN 31_CD December_NNP ,_, together_RB with_IN the_DT periods_NNS for_IN which_WDT the_DT rates_NNS were_VBD xed_VBN ,_, are_VBP set_VBN out_RP in_IN the_DT table_NN below_IN :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Average_JJ Average_JJ Average_JJ Average_JJ interest_NN rate_NN years_NNS to_TO Average_JJ years_NNS to_TO interest_NN rate_NN years_NNS to_TO Average_JJ years_NNS to_TO of_IN xed_JJ rate_NN maturity_NN of_IN maturity_NN of_IN nonof_JJ xed_JJ rate_NN maturity_NN of_IN maturity_NN of_IN nonliabilities_NNS xed_VBN rate_NN interest_NN bearing_VBG liabilities_NNS xed_VBN rate_NN interest_NN bearing_VBG %_NN liabilities_NNS financial_JJ liabilities_NNS %_NN liabilities_NNS financial_JJ liabilities_NNS Sterling_NNP 5.0_CD 0.0_CD 1.5_CD 8.0_CD n_NN a_DT US_NNP dollars_NNS 8.6_CD 2.4_CD 0.0_CD 7.3_CD 3.2_CD 0.0_CD Euro_NNP 3.4_CD 6.4_CD 0.5_CD 1.3_CD Danish_JJ kroner_NN 6.0_CD 1.2_CD 2.7_CD 6.0_CD 0.5_CD 3.7_CD Norwegian_JJ kroner_NN 3.9_CD 1.5_CD 2.4_CD 4.3_CD 1.1_CD Other_JJ currencies_NNS 5.5_CD 1.2_CD 5.9_CD 2.3_CD 4.2_CD 1.5_CD 0.9_CD 7.3_CD 2.4_CD 0.5_CD Financial_NNP liabilities_NNS are_VBP analyzed_VBN as_IN :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD NonNonFixed_NNP Floating_VBG interest_NN Fixed_VBN Floating_VBG interest_NN rate_NN rate_NN bearing_VBG Total_JJ rate_NN rate_NN bearing_VBG Total_JJ m_NN m_FW m_FW m_FW m_FW m_FW m_FW m_FW Bank_NNP loans_NNS and_CC overdrafts_NNS 15.3_CD 62.8_CD 6.6_CD 84.7_CD 12.2_CD 5.7_CD 5.6_CD 23.5_CD Finance_NNP lease_NN obligations_NNS 2.8_CD 2.8_CD 3.0_CD 3.0_CD Unsecured_JJ loan_NN notes_NNS 123.4_CD 123.4_CD 152.3_CD 152.3_CD Currency_NN and_CC interest_NN rate_NN swaps_NNS 31.1_CD 31.1_CD 17.2_CD 17.2_CD Other_JJ financial_JJ liabilities_NNS 7.8_CD 2.4_CD 10.2_CD 3.6_CD 0.8_CD 4.4_CD Non-equity_JJ minority_NN interest_NN 42.6_CD 42.6_CD 115.4_CD 96.7_CD 9.0_CD 221.1_CD 193.5_CD 25.9_CD 6.4_CD 225.8_CD Floating_VBG rate_NN interest_NN on_IN bank_NN loans_NNS and_CC overdrafts_NNS is_VBZ based_VBN on_IN local_JJ bank_NN base_NN rates_NNS ,_, and_CC the_DT oating_NN rate_NN interest_NN on_IN swaps_NNS is_VBZ based_VBN on_IN LIBOR_NNP ._.
Amersham_NNP plc_NN 69_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 20_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD The_DT groups_NNS principal_JJ xed_VBN rate_NN debt_NN obligations_NNS are_VBP three_CD series_NN of_IN US_NNP private_JJ placement_NN unsecured_JJ loan_NN notes_NNS with_IN the_DT following_JJ rates_NNS and_CC maturities_NNS :_: Amount_NNP Interest_NNP rate_NN Series_NNP $_$ m_CD %_NN Maturity_NNP Series_NNP B_NNP 15_CD 8.79_CD February_NNP 2005_CD Series_NNP C_NNP 163_CD 8.77_CD November_NNP 2004_CD Series_NNP D_NNP 15_CD 8.97_CD November_NNP 2009_CD The_DT carrying_NN value_NN of_IN Series_NNP C_NNP and_CC D_NNP notes_VBZ includes_VBZ a_DT fair_JJ value_NN adjustment_NN of_IN 3.5_CD m_NN 2001_CD 5.4_CD m_NN ,_, which_WDT arose_VBD on_IN the_DT acquisition_NN of_IN the_DT debt_NN instruments_NNS at_IN the_DT time_NN of_IN the_DT merger_NN with_IN Nycomed_NNP ._.
The_DT interest_NN rate_NN of_IN US_NNP dollar_NN xed_VBD rate_NN liabilities_NNS is_VBZ adjusted_VBN for_IN the_DT partial_JJ unwinding_VBG of_IN this_DT fair_JJ value_NN adjustment_NN during_IN the_DT periods_NNS reported_VBD ._.
b_NN Currency_NN and_CC interest_NN rate_NN composition_NN of_IN financial_JJ assets_NNS of_IN the_DT group_NN The_DT following_JJ tables_NNS analyze_VBP the_DT currency_NN and_CC interest_NN rate_NN composition_NN of_IN the_DT groups_NNS financial_JJ assets_NNS at_IN 31_CD December_NNP ._.
The_DT financial_JJ assets_NNS comprise_VBP cash_NN at_IN bank_NN ,_, short_JJ term_NN deposits_NNS ,_, trade_NN investments_NNS and_CC interest_NN bearing_NN investments_NNS plus_CC any_DT long_JJ term_NN contractual_JJ rights_NNS to_TO receive_VB cash_NN or_CC other_JJ financial_JJ assets_NNS from_IN third_JJ parties_NNS ._.
The_DT interest_NN rates_NNS on_IN the_DT majority_NN of_IN oating_NN rate_NN financial_JJ assets_NNS are_VBP based_VBN on_IN local_JJ market_NN oating_NN rates_NNS ._.
The_DT average_JJ interest_NN rates_NNS for_IN the_DT financial_JJ assets_NNS of_IN the_DT group_NN at_IN 31_CD December_NNP ,_, together_RB with_IN the_DT period_NN for_IN which_WDT the_DT rates_NNS were_VBD xed_VBN ,_, are_VBP as_IN follows_VBZ :_: 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 12_CD months_NNS to_TO 31_CD Dec_NNP 2001_CD Average_JJ years_NNS to_TO Average_JJ years_NNS Average_JJ Average_JJ maturity_NN of_IN Average_JJ Average_JJ to_TO maturity_NN of_IN interest_NN rate_NN years_NNS to_TO non-interest_JJ interest_NN rate_NN years_NNS to_TO non-interest_JJ of_IN xed_JJ rate_NN maturity_NN of_IN bearing_NN of_IN xed_JJ rate_NN maturity_NN of_IN bearing_VBG assets_NNS xed_VBN rate_NN financial_JJ assets_NNS xed_VBD rate_NN financial_JJ %_NN assets_NNS assets_NNS %_NN assets_NNS assets_NNS Sterling_NNP 3.7_CD 0.0_CD 0.0_CD 3.7_CD 0.1_CD 0.1_CD US_NNP dollars_NNS 3.9_CD 0.3_CD 0.4_CD 8.2_CD 1.8_CD 0.6_CD Japanese_JJ yen_NNS 0.0_CD Euro_NNP 2.0_CD 0.0_CD 0.2_CD 6.8_CD 4.3_CD 0.0_CD Norwegian_JJ kroner_NN 2.8_CD 0.3_CD 0.8_CD 6.7_CD 0.1_CD Danish_JJ kroner_NN 1.9_CD 8.9_CD 0.0_CD Swedish_JJ kronor_NN 0.2_CD 0.0_CD 0.0_CD Other_JJ currencies_NNS 3.8_CD 0.0_CD 0.0_CD 1.8_CD 0.1_CD 0.0_CD 3.3_CD 0.1_CD 0.1_CD 6.4_CD 1.0_CD 0.4_CD 70_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 20_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Financial_JJ assets_NNS are_VBP analyzed_VBN as_IN follows_VBZ :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD NonNonFixed_NNP Floating_VBG interest_NN Fixed_VBN Floating_VBG interest_NN rate_NN rate_NN bearing_VBG Total_JJ rate_NN rate_NN bearing_VBG Total_JJ m_NN m_FW m_FW m_FW m_FW m_FW m_FW m_FW Cash_NN at_IN bank_NN and_CC in_IN hand_NN 1.7_CD 24.3_CD 6.7_CD 32.7_CD 1.2_CD 43.3_CD 12.4_CD 56.9_CD Short_JJ term_NN deposits_NNS 0.4_CD 4.4_CD 17.3_CD 22.1_CD 20.0_CD 74.4_CD 2.1_CD 96.5_CD Interest_NN bearing_NN investments_NNS 2.9_CD 2.9_CD Equity_NN investments_NNS 8.1_CD 8.1_CD 12.8_CD 12.8_CD Other_JJ financial_JJ assets_NNS 0.4_CD 4.7_CD 5.1_CD 0.8_CD 5.6_CD 6.4_CD 2.5_CD 28.7_CD 36.8_CD 68.0_CD 24.9_CD 117.7_CD 32.9_CD 175.5_CD In_IN addition_NN to_TO the_DT financial_JJ liabilities_NNS and_CC financial_JJ assets_NNS disclosed_VBN above_IN ,_, the_DT group_NN has_VBZ granted_VBN put_JJ options_NNS over_IN shares_NNS in_IN Corixa_NNP Corporation_NNP ,_, Cimarron_NNP Software_NNP Inc._NNP and_CC Imaging_NNP Research_NNP Inc._NNP and_CC holds_VBZ call_JJ options_NNS over_IN shares_NNS in_IN Cimarron_NNP Software_NNP Inc._NNP ._.
Imaging_NNP Research_NNP Inc._NNP and_CC Analytica_NNP of_IN Branford_NNP which_WDT meet_VBP the_DT denition_NN of_IN financial_JJ instruments_NNS ._.
The_DT maximum_NN potential_JJ aggregate_JJ cash_NN consideration_NN under_IN these_DT contracts_NNS is_VBZ US$_$ 71.5_CD m._FW These_DT options_NNS expire_VBP by_IN 2006_CD ._.
c_NN Maturity_NN of_IN financial_JJ liabilities_NNS The_DT maturity_NN of_IN the_DT groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP is_VBZ analyzed_VBN as_IN follows_VBZ :_: Bank_NNP Finance_NNP Other_JJ Non-equity_JJ loans_NNS and_CC lease_NN Unsecured_JJ financial_JJ minority_NN overdrafts_NNS obligations_NNS loan_NN notes_VBZ liabilities_NNS interest_NN Total_JJ 31_CD December_NNP 2002_CD m_FW m_FW m_FW m_FW m_FW m_FW Analysis_NN by_IN year_NN of_IN repayment_NN Due_JJ within_IN one_CD year_NN or_CC on_IN demand_NN 16.2_CD 0.3_CD 1.9_CD 1.5_CD 19.9_CD Between_IN one_CD and_CC two_CD years_NNS 3.0_CD 0.3_CD 102.9_CD 1.5_CD 107.7_CD Between_IN two_CD and_CC five_CD years_NNS 65.2_CD 0.6_CD 9.8_CD 7.2_CD 82.8_CD In_IN five_CD years_NNS or_CC more_JJR 0.3_CD 1.6_CD 8.8_CD 10.7_CD Due_JJ after_IN more_JJR than_IN one_CD year_NN 68.5_CD 2.5_CD 121.5_CD 8.7_CD 201.2_CD Total_JJ repayments_NNS 84.7_CD 2.8_CD 123.4_CD 10.2_CD 221.1_CD Bank_NNP Finance_NNP Other_JJ Non-equity_JJ loans_NNS and_CC lease_NN Unsecured_JJ financial_JJ minority_NN overdrafts_NNS obligations_NNS loan_NN notes_VBZ liabilities_NNS interest_NN Total_JJ 31_CD December_NNP 2001_CD m_FW m_FW m_FW m_FW m_FW m_FW Analysis_NN by_IN year_NN of_IN repayment_NN Due_JJ within_IN one_CD year_NN or_CC on_IN demand_NN 14.8_CD 0.3_CD 15.7_CD 2.2_CD 33.0_CD Between_IN one_CD and_CC two_CD years_NNS 2.0_CD 0.3_CD 2.0_CD 0.7_CD 5.0_CD Between_IN two_CD and_CC five_CD years_NNS 6.7_CD 0.7_CD 124.7_CD 1.5_CD 133.6_CD In_IN five_CD years_NNS or_CC more_JJR 1.7_CD 9.9_CD 42.6_CD 54.2_CD Due_JJ after_IN more_JJR than_IN one_CD year_NN 8.7_CD 2.7_CD 136.6_CD 2.2_CD 42.6_CD 192.8_CD Total_JJ repayments_NNS 23.5_CD 3.0_CD 152.3_CD 4.4_CD 42.6_CD 225.8_CD The_DT group_NN has_VBZ undrawn_JJ committed_JJ borrowing_NN facilities_NNS available_JJ to_TO it_PRP at_IN 31_CD December_NNP as_IN follows_VBZ :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Expiring_VBG within_IN one_CD year_NN 430.0_CD Expiring_VBG between_IN four_CD years_NNS and_CC five_CD years_NNS 404.3_CD 404.3_CD 430.0_CD Amersham_NNP plc_NN 71_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 20_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD d_SYM Currency_NNP risk_NN exposure_NN The_DT following_VBG table_NN shows_VBZ the_DT currency_NN exposure_NN of_IN the_DT net_JJ monetary_JJ assets_NNS and_CC liabilities_NNS of_IN group_NN companies_NNS at_IN 31_CD December_NNP ._.
The_DT exposures_NNS arise_VBP where_WRB monetary_JJ assets_NNS and_CC liabilities_NNS are_VBP denominated_VBN in_IN currencies_NNS other_JJ than_IN the_DT functional_JJ currency_NN of_IN the_DT operating_VBG company_NN in_IN which_WDT they_PRP are_VBP held_VBN ._.
The_DT gains_NNS or_CC losses_NNS on_IN these_DT monetary_JJ assets_NNS and_CC liabilities_NNS are_VBP recorded_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Japanese_JJ Norwegian_JJ Swedish_JJ Sterling_NN US_NNP dollars_NNS yen_NN Euro_NNP kroner_NN kronor_NNS Other_JJ Total_NNP 31_CD December_NNP 2002_CD m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW Functional_JJ currency_NN of_IN operating_VBG company_NN Sterling_NNP 8.9_CD 1.8_CD 1.8_CD 7.6_CD 0.6_CD 3.2_CD 12.7_CD US_NNP dollars_NNS 0.1_CD 0.1_CD Japanese_JJ yen_NN 0.3_CD 1.6_CD 1.3_CD Euro_NNP 0.9_CD 5.6_CD 1.2_CD 0.3_CD 5.6_CD Norwegian_JJ kroner_NN 7.5_CD 1.8_CD 16.1_CD 6.5_CD 0.1_CD 9.4_CD 22.8_CD Swedish_JJ kronor_NN 3.8_CD 9.8_CD 1.8_CD 7.4_CD 0.2_CD 7.8_CD Other_JJ currencies_NNS 0.1_CD 13.5_CD 0.7_CD 5.0_CD 0.1_CD 19.4_CD 4.2_CD 5.4_CD 16.1_CD 1.6_CD 1.4_CD 0.8_CD 12.2_CD 30.5_CD Japanese_JJ Norwegian_JJ Swedish_JJ Sterling_NN US_NNP dollars_NNS yen_NN Euro_NNP kroner_NN kronor_NNS Other_JJ Total_NNP 31_CD December_NNP 2001_CD m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW Functional_JJ currency_NN of_IN operating_VBG company_NN Sterling_NNP 15.3_CD 0.9_CD 11.9_CD 7.0_CD 9.7_CD 3.0_CD 16.2_CD US_NNP dollars_NNS 3.4_CD 1.6_CD 5.0_CD Japanese_JJ yen_NNS 1.7_CD 1.7_CD Euro_NNP 0.4_CD 3.7_CD 0.1_CD 0.3_CD 0.1_CD 3.8_CD Norwegian_JJ kroner_NN 3.0_CD 5.5_CD 2.7_CD 4.5_CD 0.1_CD 0.4_CD 5.0_CD Swedish_JJ kronor_NNS 4.0_CD 11.6_CD 3.9_CD 3.3_CD 0.3_CD 1.8_CD 2.5_CD Other_JJ currencies_NNS 3.2_CD 4.0_CD 0.8_CD 10.0_CD 3.0_CD 5.7_CD 4.1_CD 10.8_CD 9.9_CD 2.7_CD 26.6_CD e_SYM Fair_NNP values_NNS and_CC disclosures_NNS The_DT estimated_VBN book_NN values_NNS and_CC fair_JJ values_NNS of_IN the_DT groups_NNS financial_JJ instruments_NNS at_IN 31_CD December_NNP are_VBP set_VBN out_RP below_IN :_: Primary_JJ financial_JJ instruments_NNS held_VBN or_CC issued_VBN to_TO finance_VB the_DT groups_NNS operations_NNS 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Book_NNP value_NN Fair_NNP value_NN Book_NN value_NN Fair_NNP value_NN m_NN m_FW m_FW m_FW 1_CD Cash_NN at_IN bank_NN 32.7_CD 32.7_CD 56.9_CD 56.9_CD 1_CD Short_JJ term_NN deposits_NNS 22.1_CD 22.1_CD 96.5_CD 96.5_CD 1_CD Interest_NN bearing_NN investments_NNS 2.9_CD 2.9_CD 2_CD Equity_NN investments_NNS 8.1_CD 6.2_CD 12.8_CD 11.4_CD 3_CD Other_JJ financial_JJ assets_NNS 5.1_CD 5.1_CD 6.4_CD 6.6_CD 1_CD Bank_NNP loans_NNS and_CC overdrafts_NNS 84.7_CD 84.7_CD 23.5_CD 23.5_CD 4_CD Non-equity_NN minority_NN interest_NN 42.6_CD 42.6_CD 1_CD Finance_NNP lease_NN obligations_NNS 2.8_CD 2.8_CD 3.0_CD 3.0_CD 5_CD Other_JJ financial_JJ liabilities_NNS 10.2_CD 10.2_CD 4.4_CD 4.4_CD 6_CD Unsecured_JJ loan_NN notes_NNS 123.4_CD 140.0_CD 152.3_CD 171.0_CD 1_CD The_DT fair_JJ values_NNS of_IN cash_NN ,_, short_JJ term_NN deposits_NNS ,_, interest_NN bearing_NN investments_NNS excluding_VBG subordinated_JJ loan_NN notes_NNS and_CC overdrafts_NNS approximate_JJ to_TO carrying_VBG values_NNS due_JJ to_TO the_DT short_JJ maturity_NN period_NN of_IN these_DT financial_JJ assets_NNS ._.
The_DT difference_NN between_IN carrying_VBG value_NN and_CC fair_JJ value_NN is_VBZ also_RB considered_VBN to_TO be_VB immaterial_JJ for_IN oating_VBG rate_NN bank_NN loans_NNS and_CC finance_NN lease_NN obligations_NNS ._.
Interest_NN bearing_NN investments_NNS included_VBD subordinated_JJ loan_NN notes_NNS that_WDT were_VBD valued_VBN by_IN discounting_VBG the_DT associated_VBN future_JJ cash_NN ows_VBZ to_TO 31_CD December_NNP 2001_CD ._.
The_DT difference_NN between_IN carrying_VBG value_NN and_CC fair_JJ value_NN was_VBD considered_VBN immaterial_JJ ._.
2_CD Equity_NNP investments_NNS represent_VBP equity_NN holdings_NNS in_IN trade_NN investments_NNS ._.
The_DT fair_JJ value_NN of_IN listed_VBN investments_NNS is_VBZ equal_JJ to_TO the_DT year_NN end_NN market_NN price_NN ._.
3_CD Other_JJ financial_JJ assets_NNS include_VBP investments_NNS in_IN unit_NN trusts_NNS and_CC capital_NN funds_NNS that_WDT are_VBP valued_VBN at_IN market_NN value_NN ._.
4_CD The_DT non-equity_JJ minority_NN interest_NN represents_VBZ 45_CD %_NN of_IN the_DT 8_CD %_NN non-equity_JJ redeemable_JJ cumulative_JJ preference_NN shares_NNS of_IN Amersham_NNP Biosciences_NNP ,_, which_WDT was_VBD extinguished_VBN in_IN 2002_CD on_IN the_DT purchase_NN of_IN the_DT 45_CD %_NN minority_NN in_IN Amersham_NNP Biosciences_NNPS ._.
5_CD Other_JJ financial_JJ liabilities_NNS largely_RB comprise_VBP discounted_JJ deferred_VBN consideration_NN on_IN acquisitions_NNS ,_, for_IN which_WDT book_NN value_NN is_VBZ not_RB materially_RB different_JJ to_TO fair_JJ value_NN ._.
6_CD The_DT book_NN value_NN of_IN the_DT unsecured_JJ loan_NN notes_NNS includes_VBZ a_DT fair_JJ value_NN adjustment_NN of_IN 3.5_CD m_NN 2001_CD 5.4_CD m_NN ,_, that_IN arose_VBD as_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN the_DT notes_NNS at_IN the_DT time_NN of_IN the_DT merger_NN with_IN Nycomed_NNP ._.
The_DT fair_JJ value_NN quoted_VBN at_IN 31_CD December_NNP is_VBZ based_VBN on_IN the_DT present_JJ value_NN of_IN future_JJ cash_NN ows_NNS of_IN the_DT notes_NNS ._.
72_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 20_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD 7_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB interest_NN rate_NN and_CC currency_NN exposures_NNS Assets_NNPS Liabilities_NNPS Assets_NNPS Liabilities_NNPS 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2001_CD Notional_NNP Fair_NNP Notional_NNP Fair_NNP Notional_NNP Fair_NNP Notional_NNP Fair_NNP principal_JJ value_NN principal_NN value_NN principal_JJ value_NN principal_JJ value_NN m_NN m_FW m_FW m_FW m_FW m_FW m_FW m_FW Interest_NN rate_NN swaps_NNS 31.1_CD 31.1_CD 3.2_CD 51.7_CD 3.2_CD 34.5_CD 1.3_CD Forward_RB foreign_JJ exchange_NN contracts_NNS 923.4_CD 26.5_CD 890.6_CD 3.1_CD 900.6_CD 17.7_CD 873.1_CD 8.1_CD Total_JJ for_IN financial_JJ assets_NNS 954.5_CD 26.5_CD 952.3_CD 20.9_CD Total_JJ for_IN financial_JJ liabilities_NNS 921.7_CD 6.3_CD 907.6_CD 9.4_CD 7_CD Interest_NN rate_NN swaps_NNS and_CC forward_RB foreign_JJ exchange_NN contracts_NNS are_VBP stated_VBN at_IN current_JJ market_NN values_NNS ._.
f_LS Hedges_NNP As_IN explained_VBN in_IN the_DT Financial_NNP review_NN on_IN page_NN 33_CD ,_, the_DT groups_NNS policy_NN is_VBZ to_TO hedge_VB exposures_NNS to_TO interest_NN rate_NN risk_NN and_CC currency_NN exposures_NNS using_VBG a_DT variety_NN of_IN derivative_JJ financial_JJ instruments_NNS ._.
Gains_NNS and_CC losses_NNS on_IN these_DT instruments_NNS are_VBP not_RB recognized_VBN until_IN the_DT exposure_NN that_WDT is_VBZ being_VBG hedged_VBN is_VBZ itself_PRP recognized_VBN ._.
Gains_NNS or_CC losses_NNS on_IN the_DT fair_JJ value_NN of_IN financial_JJ instruments_NNS are_VBP classied_VBN as_IN unrecognised_JJ where_WRB they_PRP have_VBP not_RB yet_RB been_VBN recorded_VBN in_IN the_DT financial_JJ statements_NNS ._.
Where_WRB gains_NNS or_CC losses_NNS have_VBP crystallised_VBN ,_, but_CC are_VBP carried_VBN forward_RB in_IN the_DT balance_NN sheet_NN pending_VBG their_PRP$ recognition_NN in_IN the_DT profit_NN and_CC loss_NN account_NN in_IN a_DT future_JJ period_NN ,_, they_PRP are_VBP treated_VBN as_IN deferred_VBN ._.
The_DT following_JJ table_NN analyses_VBZ the_DT movement_NN in_IN unrecognised_JJ and_CC deferred_JJ gains_NNS or_CC losses_NNS on_IN hedge_NN instruments_NNS during_IN the_DT year_NN to_TO 31_CD December_NNP 2002_CD ._.
31_CD Dec_NNP 2002_CD Unrecognised_NNP Deferred_NNP Net_JJ Net_NN gains_VBZ gains_NNS Gains_NNS Losses_NNS losses_NNS Gains_NNS Losses_NNS losses_NNS m_VBP m_FW m_FW m_FW m_FW m_FW Unrecognised_JJ gains_NNS losses_NNS on_IN hedges_NNS At_IN 1_CD January_NNP 2002_CD 13.8_CD 8.3_CD 5.5_CD 21.9_CD 10.8_CD 11.1_CD Gains_NNS losses_NNS arising_VBG in_IN previous_JJ years_NNS that_WDT were_VBD recognized_VBN in_IN 2002_CD 12.0_CD 8.3_CD 3.7_CD 12.7_CD 6.0_CD 6.7_CD Gains_NNS losses_NNS arising_VBG before_IN 1_CD January_NNP 2003_CD that_WDT were_VBD not_RB recognized_VBN in_IN 2002_CD 1.8_CD 1.8_CD 9.2_CD 4.8_CD 4.4_CD Gains_NNS losses_NNS arising_VBG in_IN 2002_CD that_WDT were_VBD not_RB recognized_VBN in_IN 2002_CD 17.5_CD 1.0_CD 16.5_CD 14.2_CD 1.0_CD 15.2_CD Unrecognised_JJ gains_NNS losses_NNS on_IN hedges_NNS at_IN 31_CD December_NNP 2002_CD 19.3_CD 1.0_CD 18.3_CD 23.4_CD 3.8_CD 19.6_CD Of_IN which_WDT Gains_NNS losses_NNS expected_VBN to_TO be_VB recognized_VBN in_IN 2003_CD 17.9_CD 1.0_CD 16.9_CD 15.5_CD 3.8_CD 11.7_CD Gains_NNS losses_NNS expected_VBN to_TO be_VB recognized_VBN in_IN 2004_CD or_CC later_RB 1.4_CD 1.4_CD 7.9_CD 7.9_CD As_IN at_IN 31_CD December_NNP 2002_CD the_DT company_NN has_VBZ outstanding_JJ foreign_JJ exchange_NN contracts_NNS with_IN commercial_JJ banks_NNS ,_, as_IN set_VBN out_RP in_IN the_DT following_VBG table_NN :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Principal_NN Principal_NN Principal_NN Principal_NN receivable_JJ payable_JJ Total_JJ receivable_NN payable_JJ Total_JJ m_NN m_FW m_FW m_FW m_FW m_FW Held_FW to_TO manage_VB assets_NNS and_CC liabilities_NNS 525.4_CD 507.9_CD 17.5_CD 425.8_CD 416.9_CD 8.9_CD Held_VBN to_TO manage_VB transaction_NN exposures_NNS 398.0_CD 382.7_CD 15.3_CD 474.8_CD 456.2_CD 18.6_CD 923.4_CD 890.6_CD 32.8_CD 900.6_CD 873.1_CD 27.5_CD Amersham_NNP plc_NN 73_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 20_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD The_DT contracts_NNS held_VBD to_TO manage_VB assets_NNS and_CC liabilities_NNS at_IN 31_CD December_NNP 2002_CD ,_, can_MD be_VB analyzed_VBN as_IN follows_VBZ :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Principal_NN Principal_NN Principal_NN Principal_NN receivable_JJ payable_JJ Total_JJ receivable_NN payable_JJ Total_JJ m_NN m_FW m_FW m_FW m_FW m_FW US_PRP dollars_NNS 43.5_CD 250.1_CD 206.6_CD 41.5_CD 197.8_CD 156.3_CD Japanese_JJ yen_NN 2.9_CD 79.2_CD 76.3_CD 5.2_CD 99.9_CD 94.7_CD Sterling_NNP 58.2_CD 110.1_CD 51.9_CD 52.3_CD 35.7_CD 16.6_CD Euros_NNP 36.0_CD 15.1_CD 20.9_CD 99.7_CD 44.4_CD 55.3_CD Norwegian_JJ kroner_NN 372.6_CD 11.9_CD 360.7_CD 154.3_CD 15.3_CD 139.0_CD Other_JJ currencies_NNS 12.2_CD 41.5_CD 29.3_CD 72.1_CD 23.8_CD 48.3_CD 525.4_CD 507.9_CD 17.5_CD 425.1_CD 416.9_CD 8.2_CD 21_CD Financial_NNP commitments_NNS The_DT group_NN has_VBZ commitments_NNS to_TO make_VB research_NN and_CC development_NN milestone_NN payments_NNS and_CC payments_NNS under_IN licence_NN agreements_NNS to_TO third_JJ parties_NNS subject_JJ to_TO achievement_NN of_IN agreed_VBN stages_NNS of_IN product_NN development_NN ._.
At_IN 31_CD December_NNP 2002_CD the_DT maximum_NN amounts_VBZ payable_JJ under_IN these_DT agreements_NNS was_VBD 10.2_CD m_NN 2001_CD 24.2_CD m._NN 22_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS Pensions_NNP Deferred_NNP Decommissioning_NNP and_CC similar_JJ Disposal_NNP Other_JJ tax_NN and_CC efuent_JJ costs_NNS obligations_NNS costs_NNS provisions_NNS Total_JJ m_NN m_FW m_FW m_FW m_FW m_FW Group_NNP At_IN 1_CD January_NNP 2002_CD as_IN previously_RB stated_VBN 21.1_CD 63.2_CD 88.2_CD 19.7_CD 27.8_CD 220.0_CD Prior_RB year_NN adjustment_NN 20.8_CD 20.8_CD At_IN 1_CD January_NNP 2002_CD as_IN restated_VBN 41.9_CD 63.2_CD 88.2_CD 19.7_CD 27.8_CD 240.8_CD Foreign_JJ currency_NN translation_NN 0.5_CD 1.1_CD 0.2_CD 1.0_CD 0.2_CD Transfer_NNP of_IN deferred_JJ tax_NN assets_NNS 2.9_CD 2.9_CD Transfer_NNP to_TO current_JJ tax_NN creditor_NN 2.1_CD 2.1_CD Adjustment_NNP relating_VBG to_TO fair_JJ value_NN 0.3_CD 0.3_CD Charge_NNP to_TO profit_VB and_CC loss_NN 23.1_CD 5.1_CD 14.7_CD 0.2_CD 2.3_CD 45.4_CD Charge_NNP to_TO statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 5.4_CD 5.4_CD Utilised_VBN during_IN the_DT year_NN 3.9_CD 11.3_CD 9.3_CD 4.9_CD 29.4_CD Exceptional_JJ item_NN 9.2_CD 9.2_CD At_IN 31_CD December_NNP 2002_CD 61.5_CD 65.5_CD 91.5_CD 9.6_CD 25.4_CD 253.5_CD Company_NN At_IN 1_CD January_NNP 2002_CD 51.9_CD 8.6_CD 6.7_CD 67.2_CD Charged_VBN to_TO profit_VB and_CC loss_NN 7.5_CD 2.0_CD 0.3_CD 2.9_CD 12.7_CD Utilised_VBN during_IN the_DT year_NN 1.1_CD 1.0_CD 4.4_CD 6.5_CD At_IN 31_CD December_NNP 2002_CD 7.5_CD 52.8_CD 7.9_CD 5.2_CD 73.4_CD A_DT further_JJ analysis_NN of_IN the_DT deferred_VBN taxation_NN provision_NN is_VBZ given_VBN in_IN note_NN 23_CD ._.
The_DT prior_JJ year_NN adjustment_NN relates_VBZ to_TO the_DT introduction_NN of_IN FRS19_NNP ,_, Deferred_NNP Taxation_NNP ,_, as_IN explained_VBN in_IN note_NN 36_CD ._.
Provisions_NNS for_IN decommissioning_VBG and_CC efuent_JJ costs_NNS relate_VBP to_TO the_DT costs_NNS ,_, determined_VBN on_IN a_DT going_VBG concern_NN basis_NN ,_, associated_VBN with_IN decommissioning_VBG radioactive_JJ facilities_NNS and_CC with_IN the_DT eventual_JJ disposal_NN of_IN the_DT groups_NNS intermediate_JJ level_NN waste_NN which_WDT arises_VBZ from_IN operations_NNS ._.
Decommissioning_VBG costs_NNS will_MD be_VB incurred_VBN after_IN the_DT facilities_NNS are_VBP withdrawn_VBN from_IN use_NN in_IN radioactive_JJ operations_NNS and_CC extend_VB out_RP to_TO 2036_CD ._.
Total_JJ decommissioning_NN and_CC efuent_JJ costs_NNS to_TO be_VB incurred_VBN in_IN the_DT next_JJ 10_CD years_NNS amount_NN to_TO approximately_RB 37.4_CD m._FW The_DT provisions_NNS are_VBP based_VBN on_IN the_DT latest_JJS technical_JJ assessment_NN of_IN the_DT process_NN and_CC methods_NNS likely_JJ to_TO be_VB used_VBN ,_, and_CC are_VBP stated_VBN at_IN current_JJ prices_NNS and_CC discounted_VBN using_VBG a_DT real_JJ discount_NN rate_NN of_IN 4_CD %_NN ._.
The_DT provisions_NNS for_IN pensions_NNS and_CC similar_JJ obligations_NNS primarily_RB relate_VBP to_TO pension_NN schemes_NNS ,_, details_NNS of_IN which_WDT are_VBP given_VBN in_IN note_NN 29_CD ._.
The_DT 9.6_CD m_NN provision_NN for_IN disposal_NN costs_NNS related_VBN to_TO sale_NN of_IN businesses_NNS comprises_VBZ 0.8_CD m_NN for_IN the_DT disposal_NN of_IN the_DT Tomojet_NNP business_NN in_IN 2002_CD ,_, 0.8_CD m_NN for_IN the_DT closure_NN of_IN the_DT disease_NN proling_NN project_NN in_IN 2001_CD ,_, 7.3_CD m_NN for_IN the_DT disposal_NN of_IN Nycomed_NNP Pharma_NNP in_IN 2001_CD ,_, 0.3_CD m_NN for_IN the_DT sale_NN of_IN Puerto_NNP Rico_NNP Plant_NNP in_IN 1998_CD and_CC 0.4_CD m_NN for_IN the_DT sale_NN of_IN Puridec_NNP arising_VBG in_IN 1996_CD ._.
These_DT provisions_NNS are_VBP for_IN legal_JJ or_CC constructive_JJ obligations_NNS arising_VBG from_IN the_DT sale_NN of_IN businesses_NNS and_CC are_VBP expected_VBN to_TO be_VB incurred_VBN within_IN the_DT next_JJ five_CD years_NNS ._.
Other_JJ provisions_NNS are_VBP principally_RB insurance_NN claims_NNS ,_, warranties_NNS and_CC costs_NNS associated_VBN with_IN the_DT rationalisation_NN of_IN radiopharmaceutical_JJ production_NN within_IN Amersham_NNP Health_NNP ._.
The_DT provision_NN at_IN 31_CD December_NNP 2002_CD of_IN 25.4_CD m_NN 2001_CD 27.8_CD m_NN is_VBZ made_VBN up_IN of_IN 8.0_CD m_NN 2001_CD 5.5_CD m_NN relating_VBG to_TO insurance_NN reserves_NNS ,_, 2.4_CD m_NN 2001_CD 3.0_CD m_NN relating_VBG to_TO warranties_NNS ,_, 3.8_CD m_NN 2001_CD 4.5_CD m_NN relating_VBG to_TO radiopharmaceutical_JJ rationalisation_NN costs_NNS and_CC 11.2_CD m_NN 2001_CD 14.8_CD m_NN of_IN legal_JJ and_CC other_JJ provisions_NNS ._.
74_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 23_CD Deferred_JJ taxation_NN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP Restated_NNP Note_NN m_NN m_FW m_FW m_FW Provision_NNP for_IN deferred_JJ tax_NN comprises_VBZ :_: Accelerated_JJ capital_NN allowances_NNS 22.4_CD 10.7_CD 7.0_CD Tax_NNP deductible_JJ goodwill_NN 26.2_CD 25.2_CD Capital_NN gains_NNS held_VBN over_IN 6.6_CD 2.2_CD 4.3_CD Unrealised_JJ stock_NN profit_NN 22.2_CD 18.1_CD Other_JJ short_JJ term_NN timing_NN differences_NNS 4.4_CD 8.1_CD 3.8_CD 28.6_CD 11.9_CD 7.5_CD Transfer_NNP to_TO deferred_VBN taxation_NN assets_NNS 16_CD 32.9_CD 30.0_CD 22_CD 61.5_CD 41.9_CD 7.5_CD The_DT group_NN has_VBZ a_DT potential_JJ deferred_JJ tax_NN asset_NN of_IN 28.8_CD m_NN in_IN the_DT US_NNP Biosciences_NNPS business_NN of_IN which_WDT 9.2_CD m_NN has_VBZ been_VBN recognized_VBN ,_, as_IN an_DT exceptional_JJ item_NN ,_, based_VBN on_IN future_JJ financial_JJ projections_NNS which_WDT forecast_VBP future_JJ taxable_JJ profits_NNS in_IN excess_NN of_IN those_DT arising_VBG from_IN the_DT reversal_NN of_IN deferred_JJ tax_NN liabilities_NNS ._.
The_DT remaining_VBG 19.6_CD m_NN is_VBZ not_RB recognized_VBN as_IN there_EX is_VBZ insufficient_JJ evidence_NN ,_, at_IN this_DT time_NN ,_, that_IN the_DT asset_NN will_MD be_VB recoverable_JJ in_IN the_DT foreseeable_JJ future_NN ._.
In_IN addition_NN ,_, the_DT group_NN has_VBZ further_JJ unrecognised_JJ deferred_JJ tax_NN assets_NNS of_IN 13.5_CD m_NN arising_VBG in_IN other_JJ territories_NNS ._.
These_DT relate_VBP primarily_RB to_TO tax_NN losses_NNS in_IN those_DT territories_NNS ._.
There_EX is_VBZ insufficient_JJ evidence_NN ,_, at_IN this_DT time_NN ,_, that_IN these_DT assets_NNS will_MD be_VB recoverable_JJ ._.
The_DT unrecognised_JJ assets_NNS will_MD be_VB recoverable_JJ when_WRB sufficient_JJ evidence_NN becomes_VBZ available_JJ to_TO support_VB that_DT recoverability_NN ._.
Deferred_JJ tax_NN is_VBZ measured_VBN on_IN a_DT non-discounted_JJ basis_NN at_IN the_DT tax_NN rates_NNS that_WDT are_VBP expected_VBN to_TO apply_VB in_IN the_DT periods_NNS in_IN which_WDT timing_NN differences_NNS reverse_RB ,_, based_VBN on_IN tax_NN rates_NNS and_CC laws_NNS substantively_RB enacted_VBN at_IN the_DT balance_NN sheet_NN date_NN ._.
24_CD Acquisitions_NNPS During_IN the_DT year_NN the_DT group_NN made_VBD acquisitions_NNS with_IN a_DT total_JJ consideration_NN of_IN 767.9_CD m_NN ,_, of_IN which_WDT 708.6_CD m_NN related_VBN to_TO the_DT purchase_NN of_IN the_DT 45_CD %_NN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS from_IN Pharmacia_NNP Corp._NNP a_DT Purchase_NN of_IN 45_CD %_NN minority_NN interest_NN holding_VBG in_IN Amersham_NNP Biosciences_NNP On_IN 21_CD March_NNP 2002_CD the_DT group_NN completed_VBD the_DT purchase_NN of_IN the_DT 45_CD %_NN minority_NN interest_NN holding_VBG in_IN Amersham_NNP Biosciences_NNPS that_IN it_PRP did_VBD not_RB already_RB own_VB ._.
The_DT purchase_NN consideration_NN was_VBD 704.1_CD m_NN of_IN cash_NN ,_, plus_CC costs_NNS associated_VBN with_IN the_DT purchase_NN of_IN 4.5_CD m._FW The_DT purchase_NN was_VBD nanced_VBN by_IN a_DT placing_NN of_IN 57.5_CD m_FW new_JJ ordinary_JJ shares_NNS on_IN 18_CD March_NNP 2002_CD ,_, which_WDT generated_VBD 397.0_CD m_NN after_IN costs_NNS of_IN issue_NN ,_, together_RB with_IN the_DT use_NN of_IN existing_VBG cash_NN resources_NNS and_CC drawings_NNS under_IN the_DT groups_NNS committed_VBN bank_NN facilities_NNS ._.
The_DT transaction_NN was_VBD accounted_VBN for_IN using_VBG acquisition_NN accounting_NN ._.
Goodwill_NN of_IN 692.3_CD m_NN arose_VBD on_IN the_DT transaction_NN ,_, and_CC will_MD be_VB amortised_VBN over_IN 20_CD years_NNS from_IN the_DT date_NN of_IN the_DT purchase_NN ._.
The_DT 20_CD year_NN useful_JJ life_NN reects_VBZ the_DT continuing_VBG investment_NN in_IN the_DT development_NN of_IN the_DT business_NN ._.
The_DT values_NNS ascribed_VBD to_TO the_DT net_JJ assets_NNS acquired_VBN in_IN Amersham_NNP Biosciences_NNP ,_, and_CC details_NNS of_IN the_DT fair_JJ value_NN adjustments_NNS ,_, which_WDT are_VBP provisional_JJ ,_, are_VBP set_VBN out_RP below_IN :_: Book_NNP value_NN Fair_NN value_NN at_IN 21_CD Mar_NNP at_IN 21_CD Mar_NNP 2002_CD Revaluation_NNP Other_JJ 2002_CD m_FW m_FW m_FW m_FW Tangible_JJ xed_JJ assets_NNS including_VBG investments_NNS 205.0_CD 27.2_CD 232.2_CD Intangible_NNP xed_VBD assets_NNS 146.9_CD 142.0_CD 4.9_CD 351.9_CD 27.2_CD 142.0_CD 237.1_CD Current_JJ assets_NNS including_VBG intra-group_JJ deposits_NNS of_IN 60m_JJ 353.4_CD 353.4_CD Current_JJ liabilities_NNS including_VBG intra-group_JJ loans_NNS of_IN 339m_CD 482.1_CD 482.1_CD Net_JJ current_JJ liabilities_NNS 128.7_CD 128.7_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 223.2_CD 27.2_CD 142.0_CD 108.4_CD Non-current_JJ liabilities_NNS 25.2_CD 25.2_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS 47.6_CD 0.6_CD 47.0_CD 150.4_CD 27.8_CD 142.0_CD 36.2_CD Net_JJ assets_NNS acquired_VBN 45_CD %_NN 16.3_CD Cost_NN of_IN acquisition_NN cash_NN consideration_NN 704.1_CD Acquisition_NNP expenses_NNS professional_JJ fees_NNS and_CC tax_NN costs_NNS 4.5_CD Goodwill_NNP arising_VBG on_IN acquisition_NN 692.3_CD Amersham_NNP plc_NN 75_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 24_CD Acquisitions_NNS continued_VBD The_DT other_JJ adjustment_NN relates_VBZ to_TO goodwill_NN in_IN the_DT Amersham_NNP Biosciences_NNPS balance_NN sheet_NN eliminated_VBN on_IN the_DT purchase_NN of_IN the_DT minority_NN interest_NN ._.
No_DT accounting_NN policy_NN alignment_NN adjustments_NNS are_VBP required_VBN as_IN Amersham_NNP Biosciences_NNP accounting_NN policies_NNS are_VBP consistent_JJ with_IN those_DT of_IN the_DT Amersham_NNP group_NN ._.
Tangible_JJ xed_JJ assets_NNS have_VBP been_VBN revalued_VBN to_TO their_PRP$ fair_JJ value_NN and_CC listed_VBN investments_NNS have_VBP been_VBN written_VBN down_RP to_TO their_PRP$ market_NN value_NN ._.
Adjustments_NNS within_IN provisions_NNS for_IN liabilities_NNS and_CC charges_NNS relate_VBP to_TO the_DT funded_JJ status_NN of_IN pensions_NNS ,_, primarily_RB unrecognised_JJ actuarial_JJ gains_NNS ._.
A_DT 45_CD %_NN share_NN of_IN the_DT revaluation_NN and_CC other_JJ adjustment_NN has_VBZ been_VBN recognized_VBN in_IN the_DT group_NN accounts_VBZ ._.
As_IN the_DT purchase_NN of_IN Amersham_NNP Biosciences_NNPS is_VBZ an_DT increase_NN in_IN stake_NN ,_, the_DT profits_NNS and_CC cash_NN ows_NNS of_IN Amersham_NNP Biosciences_NNPS are_VBP already_RB contained_VBN within_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN and_CC cash_NN ow_NN statement_NN of_IN the_DT Amersham_NNP group_NN for_IN the_DT current_JJ and_CC prior_JJ year_NN ._.
The_DT minority_NN interest_NN for_IN the_DT period_NN to_TO 21_CD March_NNP 2002_CD was_VBD 0.8_CD m_NN credit_NN ,_, represented_VBN by_IN a_DT 0.6_CD m_NN charge_NN for_IN non-equity_JJ minority_NN interests_NNS and_CC 1.4_CD m_NN credit_NN for_IN equity_NN minority_NN interests_NNS ._.
The_DT purchase_NN of_IN the_DT 45_CD %_NN minority_NN interest_NN was_VBD partly_RB achieved_VBN by_IN the_DT group_NN acquiring_VBG a_DT 100_CD %_NN interest_NN in_IN Pharmacia_NNP Biosystems_NNPS AB_NNP ,_, now_RB known_VBN as_IN Amersham_NNP Biosystems_NNPS AB_NNP ,_, a_DT former_JJ trading_NN company_NN in_IN the_DT Pharmacia_NNP Corporation_NNP group_NN ._.
At_IN the_DT date_NN of_IN the_DT purchase_NN this_DT company_NN had_VBD no_DT assets_NNS or_CC liabilities_NNS ,_, apart_RB from_IN the_DT investment_NN in_IN Amersham_NNP Biosciences_NNPS ._.
Full_JJ warranties_NNS and_CC indemnities_NNS were_VBD received_VBN from_IN Pharmacia_NNP Corporation_NNP in_IN respect_NN of_IN this_DT company_NN ._.
b_NN Other_JJ acquisitions_NNS On_IN 31_CD January_NNP 2002_CD ,_, the_DT group_NN acquired_VBD 100_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN two_CD ltration_NN companies_NNS ,_, AG_NNP Technology_NNP Corp_NNP and_CC InnovaSep_NNP Technology_NNP Corp._NNP ._.
The_DT fair_JJ value_NN of_IN the_DT total_JJ consideration_NN is_VBZ 38.1_CD m_NN ,_, of_IN which_WDT 11.8_CD m_NN is_VBZ deferred_VBN consideration_NN and_CC 6.7_CD m_NN is_VBZ the_DT groups_NNS best_JJS estimate_NN of_IN deferred_VBN contingent_JJ consideration_NN ._.
The_DT deferred_JJ contingent_JJ consideration_NN is_VBZ dependent_JJ on_IN the_DT acquired_VBN companies_NNS reaching_VBG technological_JJ milestones_NNS and_CC on_IN performance_NN conditions_NNS ._.
The_DT ultimate_JJ amount_NN of_IN deferred_VBN and_CC contingent_JJ consideration_NN payable_JJ is_VBZ expected_VBN to_TO be_VB in_IN the_DT range_NN of_IN $_$ 15-33m_CD ._.
Goodwill_NN arising_VBG of_IN 36.9_CD m_NN is_VBZ being_VBG amortised_VBN over_IN 10_CD years_NNS ._.
On_IN 29_CD April_NNP 2002_CD ,_, the_DT group_NN acquired_VBD 100_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN Synthia_NNP Lab_NNP Systems_NNPS Sweden_NNP AB_NNP ._.
Goodwill_NN arising_VBG of_IN 0.5_CD m_NN is_VBZ being_VBG amortised_VBN over_IN seven_CD years_NNS ._.
On_IN 10_CD May_NNP 2002_CD ,_, the_DT group_NN acquired_VBD a_DT further_JJ 16_CD %_NN holding_NN in_IN Cimarron_NNP Software_NNP Inc_NNP ,_, taking_VBG the_DT groups_NNS total_VBP holding_VBG at_IN acquisition_NN to_TO 35_CD %_NN ._.
Cimarron_NNP Software_NNP Inc_NNP is_VBZ being_VBG consolidated_VBN as_IN a_DT subsidiary_NN undertaking_NN as_IN the_DT group_NN controls_VBZ the_DT company_NN through_IN a_DT shareholders_NNS agreement_NN ._.
Goodwill_NN arising_VBG of_IN 6.3_CD m_NN is_VBZ being_VBG amortised_VBN over_IN seven_CD years_NNS ._.
Since_IN 10_CD May_NNP 2002_CD ,_, the_DT group_NN has_VBZ subscribed_VBN for_IN additional_JJ allotted_JJ share_NN capital_NN in_IN Cimarron_NNP Software_NNP Inc_NNP ,_, taking_VBG its_PRP$ holding_NN at_IN the_DT year_NN end_NN to_TO 44_CD %_NN ._.
Goodwill_NN recognized_VBN on_IN the_DT post-acquisition_JJ allotments_NNS of_IN share_NN capital_NN amounts_NNS to_TO 1.7_CD m._FW The_DT group_NN has_VBZ obligations_NNS to_TO subscribe_VB for_IN a_DT further_JJ 7_CD %_NN of_IN share_NN capital_NN over_IN the_DT next_JJ three_CD years_NNS ,_, and_CC has_VBZ options_NNS to_TO acquire_VB the_DT remaining_VBG 49_CD %_NN of_IN the_DT company_NN for_IN a_DT maximum_JJ consideration_NN of_IN $_$ 33m_CD ,_, the_DT total_JJ consideration_NN payable_JJ being_VBG contingent_JJ on_IN performance_NN conditions_NNS ._.
On_IN 11_CD July_NNP 2002_CD ,_, the_DT group_NN acquired_VBD the_DT net_JJ assets_NNS of_IN Motorolas_NNP CodeLink_NNP pre-arrayed_JJ slide_NN business_NN ._.
Goodwill_NN arising_VBG of_IN 6.8_CD m_NN is_VBZ being_VBG amortised_VBN over_IN 10_CD years_NNS ._.
All_DT transactions_NNS were_VBD accounted_VBN for_IN using_VBG acquisition_NN accounting_NN ._.
The_DT groups_NNS estimated_VBN useful_JJ life_NN for_IN these_DT acquisitions_NNS reects_VBZ the_DT period_NN over_IN which_WDT the_DT group_NN expects_VBZ to_TO receive_VB benefit_NN based_VBN on_IN acquired_VBN patents_NNS and_CC technology_NN ._.
Set_VBN out_RP below_IN is_VBZ a_DT summary_NN of_IN the_DT net_JJ assets_NNS acquired_VBN and_CC provisional_JJ fair_JJ value_NN adjustments_NNS :_: Book_NNP value_NN Revaluation_NNP Fair_NNP value_NN m_NN m_FW m_FW Fixed_VBN assets_NNS 6.2_CD 3.9_CD 10.1_CD Net_JJ current_JJ assets_NNS 1.8_CD 2.8_CD 1.0_CD Net_JJ assets_NNS 8.0_CD 1.1_CD 9.1_CD Net_JJ assets_NNS acquired_VBD 8.8_CD Cost_NN of_IN acquisition_NN :_: Cash_NN consideration_NN 38.2_CD Deferred_JJ consideration_NN 18.5_CD Existing_VBG trade_NN investment_NN 2.6_CD 59.3_CD Goodwill_NNP arising_VBG on_IN acquisition_NN 50.5_CD Adjustments_NNS to_TO xed_JJ assets_NNS relate_VBP to_TO recognition_NN of_IN intangible_JJ assets_NNS relating_VBG to_TO patented_JJ technology_NN acquired_VBN and_CC the_DT adjustment_NN to_TO net_JJ current_JJ assets_NNS relates_VBZ to_TO the_DT recognition_NN of_IN liabilities_NNS assumed_VBD on_IN acquisition_NN ._.
No_DT accounting_NN policy_NN alignment_NN adjustments_NNS have_VBP been_VBN recorded_VBN as_IN the_DT acquired_VBN entities_NNS accounting_VBG policies_NNS are_VBP consistent_JJ with_IN those_DT of_IN the_DT Amersham_NNP group_NN ._.
76_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 24_CD Acquisitions_NNS continued_VBD As_IN discussed_VBN above_IN ,_, goodwill_NN of_IN 1.7_CD m_NN arose_VBD on_IN the_DT acquisition_NN of_IN additional_JJ holdings_NNS in_IN Cimarron_NNP Software_NNP Inc._NNP ._.
Total_JJ goodwill_NN arising_VBG on_IN other_JJ acquisitions_NNS during_IN the_DT year_NN was_VBD 52.2_CD m._FW Included_VBN within_IN cash_NN paid_VBN for_IN acquisitions_NNS during_IN the_DT year_NN of_IN 40.6_CD m_NN in_IN the_DT group_NN cash_NN ow_NN statement_NN is_VBZ 2.4_CD m_NN for_IN milestone_NN payments_NNS relating_VBG to_TO prior_JJ year_NN acquisitions_NNS ._.
25_CD Called_VBN up_RP share_NN capital_NN Ordinary_NNP 5p_CD shares_NNS 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Authorised_NNP :_: Value_NNP 45.0_CD 45.0_CD Number_NNP 900.0_CD 900.0_CD Issued_VBN ,_, called_VBN up_RB and_CC fully_RB paid_VBN :_: Value_NNP 35.1_CD 32.1_CD Number_NNP 701.8_CD 641.7_CD During_IN the_DT year_NN a_DT total_NN of_IN 60,101,551_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT nominal_JJ value_NN 3m_NN were_VBD issued_VBN for_IN an_DT aggregate_JJ net_JJ cash_NN consideration_NN of_IN 407.7_CD m._FW Of_IN these_DT ,_, 57,500,000_CD shares_NNS were_VBD issued_VBN on_IN 18_CD March_NNP 2002_CD ,_, in_IN connection_NN with_IN the_DT placing_NN of_IN shares_NNS on_IN 12_CD March_NNP 2002_CD ,_, to_TO finance_VB the_DT purchase_NN of_IN the_DT outstanding_JJ shares_NNS in_IN Amersham_NNP Biosciences_NNP Limited_NNP for_IN cash_NN consideration_NN of_IN 397.0_CD m_NN ,_, net_NN of_IN issue_NN costs_NNS of_IN 5.5_CD m._FW The_DT shares_NNS were_VBD issued_VBN at_IN a_DT price_NN of_IN 7.00_CD per_IN share_NN ,_, and_CC the_DT market_NN price_NN on_IN the_DT 12_CD March_NNP 2002_CD was_VBD 7.365_CD per_IN share_NN ._.
The_DT 57,500,000_CD shares_NNS were_VBD allotted_VBN ,_, as_IN follows_VBZ :_: 50,000,000_CD placing_VBG shares_NNS to_TO persons_NNS nominated_VBN by_IN Morgan_NNP Stanley_NNP Securities_NNP Limited_NNP and_CC Hoare_NNP Govett_NNP Limited_NNP :_: 7,500,000_CD shares_NNS issued_VBN to_TO Morgan_NNP Stanley_NNP Securities_NNP Limited_NNP ,_, pursuant_JJ to_TO the_DT exercise_NN of_IN an_DT over-allotment_NN option_NN ._.
The_DT 50,000,000_CD placing_VBG shares_NNS were_VBD ultimately_RB allotted_VBN to_TO institutional_JJ investors_NNS ._.
A_DT further_JJ 438,890_CD shares_NNS were_VBD issued_VBN to_TO the_DT Qualifying_VBG Employee_NN Share_NN Ownership_NNP Trust_NNP QUEST_NNP for_IN an_DT aggregate_JJ net_JJ cash_NN consideration_NN of_IN 2.5_CD m._FW The_DT remaining_VBG 2,162,661_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT were_VBD issued_VBN in_IN connection_NN with_IN employee_NN share_NN option_NN schemes_NNS for_IN an_DT aggregate_JJ net_JJ cash_NN consideration_NN of_IN 8.2_CD m._FW Share_NN option_NN schemes_NNS The_DT following_JJ options_NNS remained_VBD exercisable_JJ at_IN the_DT year_NN end_NN ._.
The_DT exercise_NN of_IN options_NNS granted_VBN to_TO Executive_NNP Directors_NNS is_VBZ subject_JJ to_TO performance_NN conditions_NNS ._.
Options_NNS for_IN All_DT 6.35_CD October_NNP 2004_CD to_TO October_NNP 2007_CD 8,581,352_CD 9,150,000_CD 78_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 26_CD Share_NN premium_NN account_NN and_CC reserves_NNS Share_NN profit_NN premium_NN and_CC loss_NN Merger_NNP Other_JJ Revaluation_NNP account_NN account_NN reserve_NN reserves_NNS reserve_NN m_NN m_FW m_FW m_FW m_FW Group_NNP At_IN 1_CD January_NNP 2002_CD as_IN previously_RB stated_VBN 64.3_CD 401.5_CD 73.0_CD 21.0_CD Prior_RB year_NN adjustment_NN 4.4_CD At_IN 1_CD January_NNP 2002_CD as_IN restated_VBN 64.3_CD 405.9_CD 73.0_CD 21.0_CD Foreign_JJ currency_NN translation_NN 47.8_CD Issue_NN costs_NNS 5.5_CD Shares_NNS issued_VBN in_IN the_DT year_NN 410.2_CD Loss_NN relating_VBG to_TO Qualifying_VBG Employee_NNP Share_NNP Ownership_NNP Trust_NNP QUEST_NNP 1.2_CD Retained_VBN profit_NN for_IN the_DT year_NN 121.4_CD At_IN 31_CD December_NNP 2002_CD 469.0_CD 573.9_CD 73.0_CD 21.0_CD Company_NN At_IN 1_CD January_NNP 2002_CD as_IN previously_RB stated_VBN 64.3_CD 59.8_CD 13.5_CD Issue_NN costs_NNS 5.5_CD Shares_NNS issued_VBN in_IN the_DT year_NN 410.2_CD Loss_NN relating_VBG to_TO Qualifying_VBG Employee_NNP Share_NNP Ownership_NNP Trust_NNP QUEST_NNP 1.2_CD Revaluation_NNP of_IN xed_JJ asset_NN investment_NN 3.6_CD Retained_VBN profit_NN for_IN the_DT year_NN 15.5_CD At_IN 31_CD December_NNP 2002_CD 469.0_CD 74.1_CD 17.1_CD The_DT amounts_NNS included_VBD in_IN other_JJ reserves_NNS relate_VBP to_TO foreign_JJ subsidiary_NN undertakings_NNS and_CC represent_VBP amounts_NNS which_WDT can_MD not_RB be_VB distributed_VBN under_IN local_JJ company_NN law_NN ,_, plus_CC negative_JJ goodwill_NN arising_VBG on_IN the_DT acquisition_NN of_IN Pharmacia_NNP Biotech_NNP ._.
The_DT cumulative_JJ value_NN of_IN goodwill_NN written_VBN off_RP amounts_NNS to_TO 1,439.9_CD m_NN 2001_CD 1,439.9_CD m._NN The_DT companys_NNS profit_NN attributable_JJ to_TO shareholders_NNS is_VBZ 72.8_CD m_NN 2001_CD 66.0_CD m._NN In_IN accordance_NN with_IN the_DT groups_NNS accounting_VBG policy_NN ,_, an_DT exchange_NN gain_NN of_IN 46.4_CD m_NN 2001_CD 6.4_CD m_NN on_IN the_DT foreign_JJ currency_NN loans_NNS hedging_VBG group_NN investments_NNS has_VBZ been_VBN matched_VBN with_IN the_DT exchange_NN loss_NN on_IN those_DT investments_NNS in_IN reserves_NNS ._.
A_DT related_JJ tax_NN charge_NN of_IN 5.4_CD m_NN 2001_CD 0.3_CD m_NN credit_NN has_VBZ also_RB been_VBN offset_VBN in_IN reserves_NNS ._.
27_CD Capital_NNP commitments_NNS 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP m_FW m_FW m_FW m_FW Expenditure_NN contracted_VBD 41.3_CD 22.7_CD 13.2_CD 10.3_CD 28_CD Operating_NN and_CC finance_NN lease_NN commitments_NNS Payments_NNS which_WDT the_DT group_NN and_CC the_DT company_NN are_VBP committed_VBN to_TO make_VB during_IN the_DT following_JJ year_NN against_IN operating_VBG leases_NNS are_VBP as_IN follows_VBZ :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP Operating_NNP leases_VBZ m_FW m_FW m_FW m_FW Land_NN and_CC buildings_NNS :_: Expiring_VBG within_IN one_CD year_NN 1.3_CD 1.9_CD 0.3_CD Expiring_VBG between_IN two_CD and_CC five_CD years_NNS inclusive_JJ 10.3_CD 7.6_CD 1.6_CD 0.8_CD Expiring_VBG after_IN more_JJR than_IN five_CD years_NNS 3.1_CD 4.3_CD 1.3_CD 14.7_CD 13.8_CD 1.9_CD 2.1_CD Other_JJ leases_NNS :_: Expiring_VBG within_IN one_CD year_NN 1.4_CD 1.8_CD 0.7_CD 0.5_CD Expiring_VBG between_IN two_CD and_CC five_CD years_NNS inclusive_JJ 12.9_CD 13.8_CD 2.4_CD 3.6_CD Expiring_VBG after_IN more_JJR than_IN five_CD years_NNS 0.3_CD 14.6_CD 15.6_CD 3.1_CD 4.1_CD Amersham_NNP plc_NN 79_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 28_CD Operating_NN and_CC finance_NN lease_NN commitments_NNS continued_VBD The_DT finance_NN lease_NN obligations_NNS to_TO which_WDT the_DT group_NN and_CC the_DT company_NN are_VBP committed_VBN are_VBP as_IN follows_VBZ :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Group_NNP Group_NNP Company_NNP Company_NNP Finance_NNP lease_NN commitments_NNS m_VBP m_FW m_FW m_FW Payable_JJ within_IN one_CD year_NN 0.5_CD 0.4_CD Payable_JJ between_IN two_CD and_CC five_CD years_NNS 1.4_CD 1.5_CD Payable_JJ after_IN five_CD years_NNS 1.9_CD 2.1_CD 3.8_CD 4.0_CD Less_RBR finance_NN charges_NNS allocated_VBN to_TO future_JJ periods_NNS 1.0_CD 1.0_CD 2.8_CD 3.0_CD 29_CD Pensions_NNP UK_NNP schemes_NNS The_DT company_NN participates_VBZ in_IN a_DT variety_NN of_IN pension_NN arrangements_NNS on_IN behalf_NN of_IN its_PRP$ UK_NNP employees_NNS ._.
The_DT principal_JJ scheme_NN is_VBZ the_DT Amersham_NNP Pension_NNP Scheme_NNP ,_, which_WDT is_VBZ a_DT dened_JJ benefit_NN arrangement_NN ,_, the_DT assets_NNS of_IN which_WDT are_VBP held_VBN in_IN a_DT separate_JJ trustee_NN administered_VBN fund_NN ._.
An_DT actuarial_JJ valuation_NN of_IN this_DT scheme_NN as_IN at_IN 31_CD March_NNP 2000_CD was_VBD made_VBN by_IN Watson_NNP Wyatt_NNP ,_, an_DT independent_JJ rm_NN of_IN actuaries_NNS ,_, using_VBG the_DT projected_VBN unit_NN method_NN ._.
The_DT main_JJ assumptions_NNS adopted_VBN in_IN that_DT valuation_NN for_IN the_DT purposes_NNS of_IN the_DT UK_NNP Statement_NNP of_IN Standard_NNP Accounting_NNP Practice_NNP SSAP_NNP 24_CD ,_, Accounting_NNP for_IN Pension_NNP Costs_NNS ,_, were_VBD that_IN over_IN the_DT long_JJ term_NN the_DT rate_NN of_IN return_NN on_IN investments_NNS would_MD be_VB 6.9_CD %_NN pa_NN ,_, the_DT increase_NN in_IN pensionable_JJ pay_NN 5_CD %_NN pa_NN and_CC pensions_NNS in_IN payment_NN 3_CD %_NN pa._NN ._.
On_IN the_DT basis_NN of_IN these_DT assumptions_NNS the_DT market_NN value_NN of_IN the_DT schemes_NNS assets_NNS as_IN at_IN 31_CD March_NNP 2000_CD represented_VBD 112_CD %_NN of_IN the_DT value_NN of_IN the_DT benets_NNS to_TO members_NNS at_IN that_DT date_NN including_VBG allowance_NN for_IN future_JJ salary_NN and_CC pension_NN increases_NNS ._.
The_DT market_NN value_NN of_IN the_DT schemes_NNS assets_NNS on_IN 31_CD March_NNP 2000_CD was_VBD 209m_JJ ._.
The_DT pension_NN cost_NN in_IN the_DT companys_NNS financial_JJ statements_NNS and_CC the_DT associated_VBN amounts_NNS of_IN prepayment_NN are_VBP set_VBN out_RP below_IN :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Prepayment_NN at_IN start_NN of_IN year_NN 8.7_CD 6.8_CD Regular_JJ cost_NN 10.3_CD 9.0_CD Variation_NN from_IN regular_JJ cost_NN 1.6_CD 1.6_CD Contributions_NNS paid_VBN 10.7_CD 9.3_CD Prepayment_NN at_IN end_NN of_IN year_NN 10.7_CD 8.7_CD Overseas_JJ schemes_NNS The_DT group_NN operates_VBZ a_DT number_NN of_IN pension_NN schemes_NNS overseas_RB ,_, which_WDT have_VBP been_VBN developed_VBN in_IN line_NN with_IN ,_, and_CC are_VBP funded_VBN under_IN ,_, local_JJ practices_NNS ._.
The_DT principal_JJ overseas_JJ schemes_NNS are_VBP in_IN the_DT US_NNP ,_, Norway_NNP and_CC Sweden_NNP and_CC are_VBP mainly_RB of_IN the_DT dened_VBN benefit_NN type_NN funded_VBN via_IN separately_RB administered_VBN trusts_NNS or_CC guaranteed_VBN by_IN insurance_NN policies_NNS ._.
The_DT scheme_NN in_IN Sweden_NNP is_VBZ an_DT unfunded_JJ arrangement_NN and_CC there_EX is_VBZ an_DT unfunded_JJ arrangement_NN in_IN Norway_NNP in_IN addition_NN to_TO the_DT funded_JJ scheme_NN ._.
These_DT are_VBP provided_VBN for_IN in_IN the_DT group_NN financial_JJ statements_NNS and_CC secured_VBN on_IN the_DT ongoing_JJ business_NN ._.
Watson_NNP Wyatt_NNP have_VBP prepared_VBN pension_NN costs_NNS using_VBG actuarial_JJ valuations_NNS carried_VBD out_RP in_IN accordance_NN with_IN local_JJ requirements_NNS ,_, for_IN the_DT purposes_NNS of_IN group_NN reporting_VBG under_IN SSAP_NNP 24_CD ,_, Accounting_NNP for_IN Pension_NNP Costs_NNS ._.
A_DT surplus_NN or_CC deficit_NN is_VBZ amortised_VBN over_IN the_DT average_JJ remaining_VBG service_NN lives_NNS of_IN the_DT relevant_JJ employees_NNS using_VBG the_DT straight-line_JJ method_NN ._.
The_DT review_NN was_VBD made_VBN as_IN at_IN 1_CD January_NNP 2002_CD ,_, using_VBG the_DT projected_VBN unit_NN method_NN and_CC using_VBG the_DT following_VBG principal_NN assumptions_NNS ._.
US_NNP Norway_NNP Sweden_NNP %_NN %_NN %_NN Return_NN on_IN investment_NN 7.5_CD 6.5_CD 7.0_CD Increase_VBP in_IN pensionable_JJ salary_NN 4.5_CD 3.5_CD 4.0_CD Increase_VBP in_IN pensions_NNS in_IN payment_NN 2.0_CD 2.5_CD The_DT pension_NN cost_NN in_IN the_DT groups_NNS financial_JJ statements_NNS and_CC associated_VBN amounts_NNS of_IN provision_NN are_VBP set_VBN out_RP below_IN ,_, in_IN aggregate_NN ,_, for_IN these_DT principal_JJ overseas_JJ funded_VBN and_CC unfunded_JJ schemes_NNS ._.
80_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 29_CD Pensions_NNS continued_VBD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Funded_VBN Unfunded_JJ Funded_VBN Unfunded_JJ schemes_NNS schemes_NNS schemes_NNS schemes_NNS m_VBP m_FW m_FW m_FW Provision_NNP at_IN start_NN of_IN year_NN 18.6_CD 43.2_CD 18.8_CD 41.5_CD Foreign_JJ currency_NN translation_NN 1.6_CD 2.3_CD 0.5_CD 1.6_CD Pension_NN cost_NN 7.2_CD 4.6_CD 5.3_CD 4.0_CD Contributions_NNS pensions_NNS paid_VBD 8.2_CD 1.3_CD 6.0_CD 0.7_CD Provision_NNP at_IN end_NN of_IN year_NN 16.0_CD 48.8_CD 18.6_CD 43.2_CD On_IN the_DT basis_NN of_IN the_DT above_JJ assumptions_NNS the_DT actuarial_JJ value_NN of_IN the_DT scheme_NN assets_NNS for_IN the_DT principal_JJ overseas_JJ funded_JJ schemes_NNS was_VBD 76.0_CD m_NN 2001_CD 76.5_CD m_NN and_CC represents_VBZ 80_CD %_NN 2001_CD 87_CD %_NN of_IN the_DT actuarial_JJ value_NN of_IN benets_NNS to_TO members_NNS as_IN at_IN 1_CD January_NNP 2002_CD ,_, including_VBG allowance_NN for_IN future_JJ salary_NN and_CC pension_NN increases_NNS ._.
In_IN addition_NN to_TO the_DT schemes_NNS included_VBD in_IN the_DT above_JJ analysis_NN the_DT group_NN also_RB operates_VBZ dened_VBN benefit_NN schemes_NNS in_IN other_JJ territories_NNS ,_, principally_RB Japan_NNP and_CC Germany_NNP ._.
FRS_NNP 17_CD In_IN November_NNP 2000_CD ,_, the_DT Accounting_NNP Standards_NNP Board_NNP published_VBD FRS_NNP 17_CD Retirement_NNP Benets_NNPS to_TO replace_VB the_DT existing_VBG standard_JJ SSAP_NNP 24_CD Accounting_NN for_IN Pension_NN costs_NNS ._.
Although_IN the_DT new_JJ standard_NN does_VBZ not_RB become_VB mandatory_JJ until_IN accounting_NN periods_NNS beginning_VBG on_IN or_CC after_IN 1_CD January_NNP 2005_CD ,_, it_PRP sets_VBZ down_RP transitional_JJ arrangements_NNS which_WDT require_VBP footnote_NN disclosures_NNS in_IN the_DT interim_JJ period_NN up_IN to_TO full_JJ adoption_NN ._.
The_DT most_RBS recent_JJ actuarial_JJ valuations_NNS have_VBP been_VBN updated_VBN by_IN Watson_NNP Wyatt_NNP to_TO take_VB account_NN of_IN the_DT requirements_NNS of_IN FRS_NNP 17_CD in_IN order_NN to_TO assess_VB the_DT liabilities_NNS of_IN the_DT schemes_NNS at_IN 31_CD December_NNP 2002_CD ._.
For_IN the_DT principal_JJ overseas_JJ schemes_NNS this_DT latest_JJS valuation_NN was_VBD at_IN 31_CD December_NNP 2001_CD including_VBG both_DT the_DT US_NNP and_CC Norway_NNP and_CC at_IN 31_CD December_NNP 1999_CD for_IN Sweden_NNP ._.
Scheme_NN assets_NNS are_VBP stated_VBN at_IN their_PRP$ market_NN value_NN at_IN 31_CD December_NNP 2002_CD ._.
The_DT future_JJ agreed_VBD contribution_NN rate_NN for_IN the_DT UK_NNP scheme_NN is_VBZ currently_RB 15.2_CD %_NN ._.
This_DT is_VBZ subject_JJ to_TO review_VB during_IN 2003_CD ._.
For_IN the_DT overseas_JJ schemes_NNS the_DT contribution_NN rate_NN will_MD be_VB assessed_VBN on_IN year_NN on_IN year_NN basis_NN ._.
All_DT of_IN the_DT group_NN pension_NN schemes_NNS are_VBP open_JJ as_IN at_IN 31_CD December_NNP 2002_CD ._.
Main_NNP assumptions_NNS for_IN FRS_NNP 17_CD purposes_NNS UK_NNP US_NNP Norway_NNP Other_JJ 31_CD December_NNP 2002_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN increase_NN in_IN salaries_NNS 4.25_CD 4.25_CD 3.50_CD 3.75_CD Rate_NN of_IN increase_NN in_IN pensions_NNS in_IN payment_NN 2.25_CD 0.00_CD 2.00_CD 2.00_CD Discount_NNP rate_NN 5.50_CD 6.75_CD 6.50_CD 5.50_CD Ination_NNP 2.25_CD 3.00_CD 2.50_CD 2.50_CD UK_NNP US_NNP Norway_NNP Other_JJ 31_CD December_NNP 2001_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN increase_NN in_IN salaries_NNS 4.25_CD 4.25_CD 3.50_CD 3.25_CD Rate_NN of_IN increase_NN in_IN pensions_NNS in_IN payment_NN 2.25_CD 0.00_CD 2.00_CD 2.25_CD Discount_NNP rate_NN 5.75_CD 7.25_CD 7.00_CD 5.00_CD Ination_NNP 2.25_CD 3.00_CD 2.50_CD 2.50_CD The_DT market_NN value_NN of_IN assets_NNS in_IN the_DT schemes_NNS at_IN 31_CD December_NNP 2002_CD and_CC the_DT long_JJ term_NN expected_VBN rates_NNS of_IN return_NN at_IN that_DT date_NN were_VBD :_: 31_CD December_NNP 2002_CD Equities_NNPS Bonds_NNPS Other_JJ Total_JJ Long_JJ term_NN rate_NN of_IN return_NN expected_VBN at_IN 31_CD December_NNP 2002_CD %_NN pa_NN UK_NNP 8.50_CD 5.00_CD 6.00_CD US_NNP 8.75_CD 6.25_CD 4.50_CD Norway_NNP 8.75_CD 6.00_CD 5.00_CD Other_JJ 5.50_CD 2.50_CD 2.00_CD Value_NN at_IN 31_CD December_NNP 2002_CD m_NN UK_NNP 127.3_CD 34.5_CD 8.4_CD 170.2_CD US_NNP 29.4_CD 16.4_CD 0.7_CD 46.5_CD Norway_NNP 2.9_CD 16.7_CD 9.0_CD 28.6_CD Other_JJ 4.9_CD 3.4_CD 0.7_CD 9.0_CD Total_JJ 164.5_CD 71.0_CD 18.8_CD 254.3_CD Amersham_NNP plc_NN 81_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 29_CD Pensions_NNS continued_VBD The_DT market_NN value_NN of_IN assets_NNS in_IN the_DT schemes_NNS at_IN 31_CD December_NNP 2001_CD and_CC the_DT long_JJ term_NN expected_VBN rates_NNS of_IN return_NN at_IN that_DT date_NN were_VBD :_: 31_CD December_NNP 2001_CD Equities_NNPS Bonds_NNPS Other_JJ Total_JJ Long_JJ term_NN rate_NN of_IN return_NN expected_VBN at_IN 31_CD December_NNP 2001_CD %_NN pa_NN UK_NNP 8.00_CD 5.50_CD 5.00_CD US_NNP 8.75_CD 7.00_CD 4.50_CD Norway_NNP 8.25_CD 6.75_CD 6.00_CD Other_JJ 6.25_CD 3.00_CD 2.00_CD Value_NN at_IN 31_CD December_NNP 2001_CD m_NN UK_NNP 136.5_CD 26.7_CD 27.4_CD 190.6_CD US_NNP 32.0_CD 21.7_CD 0.7_CD 54.4_CD Norway_NNP 4.8_CD 15.2_CD 2.7_CD 22.7_CD Other_JJ 4.4_CD 3.2_CD 0.7_CD 8.3_CD Total_JJ 177.7_CD 66.8_CD 31.5_CD 276.0_CD The_DT following_JJ amounts_NNS at_IN 31_CD December_NNP 2002_CD were_VBD measured_VBN in_IN accordance_NN with_IN the_DT requirements_NNS of_IN FRS17_NNP :_: UK_NNP US_NNP Norway_NNP Other_JJ Total_NNP m_FW m_FW m_FW m_FW m_FW Total_JJ market_NN value_NN of_IN assets_NNS 170.2_CD 46.5_CD 28.6_CD 9.0_CD 254.3_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 268.3_CD 102.2_CD 33.8_CD 58.3_CD 462.6_CD deficit_NN in_IN the_DT scheme_NN 98.1_CD 55.7_CD 5.2_CD 49.3_CD 208.3_CD Related_VBN deferred_VBN tax_NN asset_NN 7.5_CD 22.3_CD 1.4_CD 15.4_CD 46.6_CD Net_JJ pension_NN liabilities_NNS 90.6_CD 33.4_CD 3.8_CD 33.9_CD 161.7_CD The_DT following_JJ amounts_NNS at_IN 31_CD December_NNP 2001_CD were_VBD measured_VBN in_IN accordance_NN with_IN the_DT requirements_NNS of_IN FRS17_NNP :_: UK_NNP US_NNP Norway_NNP Other_JJ Total_NNP m_FW m_FW m_FW m_FW m_FW Total_JJ market_NN value_NN of_IN assets_NNS 190.6_CD 54.4_CD 22.7_CD 8.3_CD 276.0_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 212.4_CD 92.2_CD 26.3_CD 48.7_CD 379.6_CD deficit_NN in_IN the_DT scheme_NN 21.8_CD 37.8_CD 3.6_CD 40.4_CD 103.6_CD Related_VBN deferred_VBN tax_NN asset_NN 15.1_CD 1.0_CD 12.5_CD 28.6_CD Net_JJ pension_NN liabilities_NNS 21.8_CD 22.7_CD 2.6_CD 27.9_CD 75.0_CD If_IN the_DT above_JJ amounts_NNS had_VBD been_VBN recognized_VBN in_IN the_DT financial_JJ statements_NNS ,_, the_DT groups_NNS net_JJ assets_NNS and_CC reserves_NNS at_IN 31_CD December_NNP 2002_CD would_MD be_VB as_IN follows_VBZ :_: 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Restated_VBN m_FW m_FW Net_JJ assets_NNS Net_JJ assets_NNS 1,176.9_CD 658.9_CD Add_VB back_RB SSAP_NNP 24_CD net_JJ pension_NN liability_NN and_CC prepayments_NNS 80.8_CD 79.5_CD Less_RBR effect_NN of_IN NMP_NNP joint_JJ venture_NN scheme_NN 0.2_CD 0.1_CD Less_RBR FRS_NNP 17_CD net_JJ pension_NN liability_NN ,_, including_VBG NMP_NNP 208.3_CD 103.6_CD Net_JJ effect_NN on_IN related_JJ deferred_JJ tax_NN asset_NN 19.6_CD 2.2_CD Impact_NN on_IN minority_NN interest_NN 0.2_CD Net_JJ assets_NNS including_VBG FRS_NNP 17_CD pension_NN liability_NN 1,068.8_CD 636.7_CD Reserves_NNS Reserves_NNS 1,136.9_CD 564.2_CD Add_VB back_RB SSAP_NNP 24_CD net_JJ pension_NN liability_NN and_CC prepayments_NNS 80.8_CD 79.5_CD Less_RBR effect_NN of_IN NMP_NNP joint_JJ venture_NN scheme_NN 0.2_CD 0.1_CD Less_RBR FRS_NNP 17_CD net_JJ pension_NN liability_NN ,_, including_VBG NMP_NNP 208.3_CD 103.6_CD Net_JJ effect_NN on_IN related_JJ deferred_JJ tax_NN asset_NN 19.6_CD 2.2_CD Impact_NN on_IN minority_NN interest_NN 0.2_CD Reserves_NNS including_VBG FRS_NNP 17_CD pension_NN liability_NN 1,028.8_CD 542.0_CD 82_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 29_CD Pensions_NNS continued_VBD The_DT amounts_NNS charged_VBN to_TO operating_VBG profit_NN under_IN FRS17_NNP would_MD have_VB been_VBN :_: UK_NNP US_NNP Norway_NNP Other_JJ Total_NNP m_FW m_FW m_FW m_FW m_FW Current_JJ service_NN cost_NN 10.7_CD 4.8_CD 1.6_CD 2.9_CD 20.0_CD Past_JJ service_NN cost_NN 0.3_CD 0.3_CD Total_JJ operating_VBG charge_NN 10.7_CD 5.1_CD 1.6_CD 2.9_CD 20.3_CD The_DT amounts_NNS charged_VBN to_TO nancing_VBG under_IN FRS17_NNP would_MD have_VB been_VBN :_: UK_NNP US_NNP Norway_NNP Other_JJ Total_NNP m_FW m_FW m_FW m_FW m_FW Expected_VBN return_NN on_IN pension_NN scheme_NN assets_NNS 14.1_CD 4.3_CD 1.8_CD 0.4_CD 20.6_CD Interest_NN on_IN pension_NN scheme_NN liabilities_NNS 12.1_CD 6.3_CD 2.0_CD 2.8_CD 23.2_CD Total_JJ nancing_VBG charge_NN income_NN 2.0_CD 2.0_CD 0.2_CD 2.4_CD 2.6_CD The_DT total_JJ pension_NN charge_NN for_IN the_DT group_NN ,_, including_VBG NMP_NNP ,_, is_VBZ 23.8_CD m._FW Excluding_VBG items_NNS outside_IN the_DT scope_NN of_IN SSAP_NNP 24_CD of_IN 0.6_CD m_NN ,_, the_DT charge_NN for_IN the_DT year_NN is_VBZ 23.1_CD m._FW The_DT effect_NN on_IN the_DT charge_NN of_IN adopting_VBG FRS_NNP 17_CD would_MD therefore_RB be_VB a_DT decrease_NN of_IN 0.2_CD m._FW Analysis_NN of_IN the_DT amount_NN that_WDT would_MD have_VB been_VBN included_VBN within_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS under_IN FRS17_NNP :_: UK_NNP US_NNP Norway_NNP Other_JJ Total_NNP m_FW m_FW m_FW m_FW m_FW Actual_JJ return_NN less_RBR expected_JJ return_NN on_IN pension_NN scheme_NN assets_NNS 44.8_CD 10.1_CD 1.4_CD 1.4_CD 57.7_CD Experience_NN gains_NNS losses_NNS arising_VBG on_IN the_DT scheme_NN liabilities_NNS 4.2_CD 2.7_CD 2.3_CD 1.3_CD 5.1_CD Changes_NNS in_IN assumptions_NNS underlying_VBG the_DT present_JJ value_NN 1_CD of_IN scheme_NN liabilities_NNS 37.7_CD 8.8_CD 2.9_CD 3.1_CD 52.5_CD Actuarial_JJ loss_NN recognized_VBN in_IN group_NN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 78.3_CD 21.6_CD 2.0_CD 3.2_CD 105.1_CD 1_CD Includes_VBZ the_DT impact_NN of_IN adopting_VBG Urgent_NNP Issues_NNP Task_NNP Force_NNP UITF_NNP No_NNP 35_CD Death-in-service_NN and_CC incapacity_NN benets_NNS ._.
The_DT analysis_NN of_IN experience_NN gains_NNS and_CC losses_NNS ,_, recognized_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ,_, is_VBZ as_IN follows_VBZ :_: UK_NNP US_NNP Norway_NNP Other_JJ Total_JJ Actual_JJ return_NN less_RBR expected_JJ return_NN on_IN pension_NN scheme_NN assets_NNS m_VBP 44.8_CD 10.1_CD 1.4_CD 1.4_CD 57.7_CD Percentage_NN of_IN scheme_NN assets_NNS at_IN end_NN of_IN year_NN %_NN 26_CD 22_CD 5_CD 16_CD 23_CD Experience_NN gains_NNS losses_NNS arising_VBG on_IN the_DT scheme_NN liabilities_NNS m_VBP 4.2_CD 2.7_CD 2.3_CD 1.3_CD 5.1_CD Percentage_NN of_IN scheme_NN liabilities_NNS at_IN end_NN of_IN year_NN %_NN 2_CD 3_CD 7_CD 2_CD 1_CD Total_JJ actuarial_JJ loss_NN recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS m_VBP 78.3_CD 21.6_CD 2.0_CD 3.2_CD 105.1_CD Percentage_NN of_IN scheme_NN liabilities_NNS at_IN end_NN of_IN year_NN %_NN 29_CD 21_CD 6_CD 5_CD 23_CD The_DT movement_NN in_IN the_DT deficit_NN during_IN the_DT year_NN under_IN FRS_NNP 17_CD would_MD have_VB been_VBN :_: UK_NNP US_NNP Norway_NNP Other_JJ Total_NNP m_FW m_FW m_FW m_FW m_FW deficit_NN in_IN the_DT scheme_NN at_IN the_DT beginning_NN of_IN the_DT year_NN 21.8_CD 37.8_CD 3.6_CD 40.4_CD 103.6_CD Movement_NNP in_IN the_DT year_NN :_: Foreign_JJ currency_NN translation_NN 5.2_CD 0.8_CD 2.9_CD 1.5_CD Current_JJ service_NN cost_NN 10.7_CD 4.8_CD 1.6_CD 2.9_CD 20.0_CD Past_NNP service_NN costs_VBZ 0.3_CD 0.3_CD Contributions_NNS 10.7_CD 5.6_CD 3.0_CD 2.5_CD 21.8_CD Other_JJ finance_NN income_NN charge_NN 2.0_CD 2.0_CD 0.2_CD 2.4_CD 2.6_CD Actuarial_JJ loss_NN 78.3_CD 21.6_CD 2.0_CD 3.2_CD 105.1_CD deficit_NN in_IN the_DT scheme_NN at_IN the_DT end_NN of_IN the_DT year_NN 98.1_CD 55.7_CD 5.2_CD 49.3_CD 208.3_CD Opening_NN related_VBN deferred_VBN tax_NN asset_NN 15.1_CD 1.0_CD 12.5_CD 28.6_CD Movement_NNP in_IN the_DT year_NN 7.5_CD 7.2_CD 0.4_CD 2.9_CD 18.0_CD Closing_NN related_VBN deferred_VBN tax_NN asset_NN 7.5_CD 22.3_CD 1.4_CD 15.4_CD 46.6_CD Amersham_NNP plc_NN 83_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 30_CD Shares_NNS in_IN group_NN undertakings_NNS Information_NNP relating_VBG to_TO subsidiary_NN ,_, joint_JJ venture_NN and_CC associated_VBN undertakings_NNS is_VBZ given_VBN on_IN those_DT that_WDT ,_, in_IN the_DT opinion_NN of_IN the_DT Directors_NNS ,_, principally_RB affected_VBD the_DT profits_NNS or_CC assets_NNS of_IN the_DT group_NN ._.
The_DT primary_JJ activity_NN of_IN the_DT majority_NN of_IN the_DT undertakings_NNS shown_VBN below_IN is_VBZ the_DT development_NN and_CC manufacture_NN and_CC or_CC sale_NN of_IN specialised_JJ products_NNS for_IN research-based_JJ biotechnology_NN supply_NN and_CC the_DT diagnosis_NN and_CC treatment_NN of_IN disease_NN ._.
Subsidiary_NNP ,_, joint_JJ venture_NN ,_, and_CC associated_VBN undertakings_NNS are_VBP listed_VBN under_IN the_DT relevant_JJ business_NN operation_NN ._.
Where_WRB the_DT relevant_JJ company_NN serves_VBZ more_JJR than_IN one_CD business_NN it_PRP is_VBZ listed_VBN under_IN the_DT dominant_JJ business_NN operation_NN ._.
With_IN the_DT exception_NN of_IN Amersham_NNP Buchler_NNP GmbH_NNP &_CC Co._NNP ._.
KG_NNP and_CC Amersham_NNP Biosciences_NNP Limited_NNP ,_, the_DT companys_NNS holdings_NNS in_IN the_DT following_VBG undertakings_NNS are_VBP represented_VBN by_IN ordinary_JJ shares_NNS ._.
Amersham_NNP Buchler_NNP GmbH_NNP &_CC Co._NNP ._.
KG_NNP is_VBZ a_DT partnership_NN in_IN which_WDT the_DT groups_NNS interest_NN is_VBZ in_IN limited_JJ liability_NN form_NN ._.
The_DT company_NN holds_VBZ ordinary_JJ and_CC non-voting_JJ preference_NN shares_NNS in_IN Amersham_NNP Biosciences_NNP Limited_NNP in_IN the_DT proportion_NN stated_VBN below_IN ._.
All_DT of_IN the_DT companies_NNS listed_VBN below_IN operate_VBP principally_RB in_IN their_PRP$ country_NN of_IN incorporation_NN or_CC registration_NN and_CC have_VBP coterminous_JJ year_NN ends_VBZ ._.
Proportion_NN of_IN nominal_JJ value_NN of_IN issued_VBN shares_NNS held_VBD Country_NN of_IN By_IN the_DT By_IN subsidiary_NN incorporation_NN company_NN undertakings_NNS or_CC registration_NN %_NN %_NN Holding_VBG companies_NNS Amersham_NNP Health_NNP Norge_NNP AS_NNP Norway_NNP 100_CD Acam_NNP Overseas_NNP Holdings_NNPS Ltd_NNP UK_NNP 100_CD Acam_NNP Holdings_NNP UK_NNP Ltd_NNP UK_NNP 100_CD Amersham_NNP Benelux_NNP BV_NNP Netherlands_NNP 100_CD Amersham_NNP Biosystems_NNPS AB_NNP Sweden_NNP 100_CD Amersham_NNP Biosciences_NNP Amersham_NNP Biosciences_NNPS Ltd_NNP UK_NNP 61_CD 39_CD Amersham_NNP Biosciences_NNP Corp_NNP USA_NNP 100_CD Amersham_NNP Biosciences_NNPS UK_NNP Ltd_NNP UK_NNP 100_CD Amersham_NNP Biosciences_NNP Europe_NNP GmbH_NNP Germany_NNP 100_CD Amersham_NNP Biosciences_NNP AB_NNP Sweden_NNP 100_CD Amersham_NNP Biosciences_NNP SV_NNP Corp_NNP USA_NNP 100_CD Amersham_NNP Biosciences_NNPS KK_NNP Japan_NNP 100_CD Amersham_NNP Biosciences_NNPS Ltd_NNP Hong_NNP Kong_NNP 100_CD AG_NNP Technology_NNP Corp_NNP USA_NNP 100_CD InnovaSep_NNP Technology_NNP Corporation_NNP USA_NNP 100_CD Amersham_NNP Health_NNP Amersham_NNP Buchler_NNP GmbH_NNP &_CC Co._NNP ._.
KG_NNP Germany_NNP 60_CD Amersham_NNP Health_NNP AS_NNP Norway_NNP 100_CD Amersham_NNP Health_NNP Ireland_NNP 100_CD Amersham_NNP Health_NNP Inc_NNP USA_NNP 100_CD Amersham_NNP Health_NNP Pte_NNP Ltd_NNP Singapore_NNP 100_CD Nycomed_NNP Amersham_NNP Sorin_NNP Srl_NNP Italy_NNP 100_CD Amersham_NNP Health_NNP Ltd_NNP China_NNP 80_CD Amersham_NNP Health_NNP Holdings_NNPS Inc_NNP USA_NNP 100_CD Joint_NNP venture_NN Amersham_NNP Health_NNP Nihon_NNP Medi-Physics_NNP Company_NNP Ltd_NNP Japan_NNP 29_CD 21_CD The_DT investment_NN in_IN Nihon_NNP Medi-Physics_NNP Company_NNP Ltd_NNP relates_VBZ to_TO ordinary_JJ shares_NNS ._.
The_DT shares_NNS carry_VBP standard_JJ pre-emption_NN rights_NNS ._.
A_DT full_JJ list_NN of_IN all_DT group_NN undertakings_NNS will_MD be_VB appended_VBN to_TO the_DT annual_JJ return_NN ._.
84_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD 31_CD Net_JJ cash_NN ow_NN from_IN operating_VBG activities_NNS 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Total_JJ operating_NN profit_NN before_IN exceptional_JJ items_NNS 273.2_CD 280.8_CD Share_NN of_IN operating_NN profit_NN of_IN joint_JJ venture_NN and_CC associates_NNS 23.2_CD 26.1_CD Depreciation_NN and_CC amortisation_NN 116.4_CD 80.0_CD Loss_NN on_IN sale_NN of_IN tangible_JJ xed_JJ assets_NNS 1.5_CD 0.3_CD Decrease_NN increase_NN in_IN provisions_NNS 6.8_CD 1.3_CD Increase_VBP in_IN stocks_NNS 19.9_CD 12.1_CD Decrease_NN increase_NN in_IN debtors_NNS 5.3_CD 16.8_CD Decrease_NN increase_NN in_IN creditors_NNS 1.0_CD 34.9_CD Net_JJ cash_NN inow_NN from_IN operating_VBG activities_NNS before_IN exceptional_JJ items_NNS 345.5_CD 342.3_CD Exceptional_JJ items_NNS 12.0_CD Net_JJ cash_NN inow_NN from_IN operating_VBG activities_NNS 345.5_CD 354.3_CD 32_CD Analysis_NN of_IN net_JJ debt_NN As_IN at_IN Exchange_NNP As_IN at_IN 1_CD Jan_NNP 2002_CD Cash_NNP ow_NN movements_NNS 31_CD Dec_NNP 2002_CD m_FW m_FW m_FW m_FW Cash_NN at_IN bank_NN and_CC in_IN hand_NN 56.9_CD 30.3_CD 6.1_CD 32.7_CD Overdrafts_NNPS 11.1_CD 4.0_CD 0.1_CD 7.2_CD 45.8_CD 26.3_CD 6.0_CD 25.5_CD Liquid_NN resources_NNS 96.5_CD 74.5_CD 0.1_CD 22.1_CD Loans_NNS due_JJ within_IN one_CD year_NN 19.7_CD 14.7_CD 3.0_CD 37.4_CD Loans_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN 148.0_CD 133.6_CD 89.1_CD 192.5_CD Net_JJ debt_NN 25.4_CD 249.1_CD 92.2_CD 182.3_CD 33_CD Reconciliation_NNP of_IN net_JJ cash_NN ow_NN to_TO movement_NN in_IN net_JJ debt_NN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Decrease_NN increase_NN in_IN cash_NN in_IN the_DT period_NN 26.3_CD 7.8_CD Cash_NN inow_NN outow_NN from_IN liquid_JJ resources_NNS 74.5_CD 91.4_CD Cash_NN inow_NN outow_NN from_IN increase_NN reduction_NN in_IN loans_NNS and_CC lease_NN finance_NN 148.3_CD 205.3_CD Change_NNP in_IN net_JJ debt_NN resulting_VBG from_IN cash_NN ows_NNS 249.1_CD 304.5_CD Exchange_NNP movements_NNS 92.2_CD 6.4_CD Movement_NNP in_IN net_JJ debt_NN in_IN the_DT period_NN 156.9_CD 298.1_CD Net_JJ debt_NN at_IN 1_CD January_NNP 25.4_CD 323.5_CD Net_JJ debt_NN at_IN 31_CD December_NNP 182.3_CD 25.4_CD 34_CD Related_VBN party_NN disclosures_NNS Apart_RB from_IN the_DT transactions_NNS noted_VBD below_IN there_EX were_VBD no_DT other_JJ material_NN items_NNS requiring_VBG disclosure_NN ._.
Transactions_NNS with_IN Nihon_NNP Medi-Physics_NNP Company_NNP Limited_NNP NMP_NNP During_IN 2002_CD the_DT group_NN made_VBD sales_NNS to_TO NMP_NNP of_IN 7.6_CD m_NN 2001_CD 6.6_CD m_NN and_CC purchases_NNS of_IN 0.1_CD m_NN 2001_CD 0.1_CD m._NN At_IN the_DT year_NN end_NN the_DT group_NN was_VBD owed_VBN 1.0_CD m_NN 2001_CD 1.3_CD m_NN in_IN respect_NN of_IN trading_NN balances_NNS and_CC the_DT group_NN owed_VBD NMP_NNP 26.2_CD m_NN 2001_CD nil_NN relating_VBG to_TO a_DT short_JJ term_NN loan_NN balance_NN ._.
Transactions_NNS with_IN Reviss_NNP Services_NNP Limited_NNP RSL_NNP During_IN 1996_CD the_DT group_NN disposed_VBD of_IN its_PRP$ Puridec_JJ business_NN to_TO RSL_NNP ,_, then_RB an_DT associated_VBN undertaking_NN ,_, for_IN a_DT consideration_NN of_IN 5.9_CD m_NN payable_JJ within_IN a_DT seven_CD year_NN period_NN ._.
At_IN 31_CD December_NNP 2002_CD the_DT group_NN held_VBD a_DT 10_CD %_NN trade_NN investment_NN in_IN RSL_NNP ._.
During_IN 2002_CD the_DT group_NN recharged_VBD RSL_NNP in_IN relation_NN to_TO the_DT provision_NN of_IN payroll_NN and_CC other_JJ services_NNS 0.8_CD m_NN 2001_CD 1.1_CD m_NN and_CC made_VBD purchases_NNS of_IN 2.9_CD m_NN 2001_CD 4.7_CD m_NN in_IN respect_NN of_IN normal_JJ trading_NN activities_NNS ._.
At_IN 31_CD December_NNP 2002_CD the_DT group_NN owed_VBD RSL_NNP 0.2_CD m_NN 2001_CD 0.1_CD m_NN and_CC was_VBD owed_VBN 0.6_CD m_NN 2001_CD 1.3_CD m_NN ,_, comprising_VBG 0.6_CD m_NN 2001_CD 0.6_CD m_NN in_IN respect_NN of_IN other_JJ services_NNS and_CC nil_NN 2001_CD -_: 0.7_CD m_NN in_IN relation_NN to_TO the_DT sale_NN of_IN the_DT Puridec_NNP business_NN ._.
Amersham_NNP plc_NN 85_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 34_CD Related_VBN party_NN disclosures_NNS continued_VBD Transactions_NNS with_IN Gyros_NNP AB_NNP During_IN the_DT year_NN the_DT group_NN made_VBD milestone_NN payments_NNS of_IN nil_NN 2001_CD 1.0_CD m_NN to_TO Gyros_NNP AB_NNP ._.
The_DT group_NN holds_VBZ a_DT 9.7_CD %_NN interest_NN in_IN Gyros_NNP AB_NNP ._.
At_IN 31_CD December_NNP 2002_CD the_DT group_NN owed_VBD Gyros_NNP AB_NNP nil_NN 2001_CD nil_NN ._.
Transactions_NNS with_IN Cimarron_NNP Software_NNP Inc_NNP From_IN 1_CD January_NNP 2002_CD to_TO 10_CD May_NNP 2002_CD the_DT group_NN held_VBD a_DT trade_NN investment_NN in_IN Cimarron_NNP Software_NNP Inc_NNP representing_VBG 19_CD %_NN of_IN that_DT companys_VBZ equity_NN ._.
During_IN the_DT period_NN to_TO 10_CD May_NNP 2002_CD the_DT group_NN paid_VBD 0.5_CD m_NN 2001_CD 1.1_CD m_NN to_TO Cimarron_NNP Software_NNP Inc._NNP in_IN respect_NN of_IN normal_JJ trading_NN activities_NNS ._.
From_IN 10_CD May_NNP 2002_CD onwards_NNS Cimarron_NNP Software_NNP Inc_NNP has_VBZ been_VBN consolidated_VBN as_IN a_DT subsidiary_NN undertaking_NN ._.
Transactions_NNS with_IN Molecular_NNP Staging_NNP Inc_NNP The_NNP group_NN holds_VBZ a_DT trade_NN investment_NN in_IN Molecular_NNP Staging_NNP Inc._NNP ._.
During_IN 2002_CD ,_, the_DT group_NN made_VBD sales_NNS of_IN nil_NN 2001_CD 0.2_CD m_NN to_TO Molecular_NNP Staging_NNP Inc_NNP ,_, and_CC made_VBD purchases_NNS of_IN 0.8_CD m_NN 2001_CD 0.4_CD m_NN ,_, in_IN respect_NN of_IN normal_JJ trading_NN activities_NNS ._.
Transactions_NNS with_IN MU_NNP Bioteknik_NNP AB_NNP During_IN the_DT year_NN ,_, the_DT group_NN made_VBD royalty_NN payments_NNS to_TO MU_NNP Bioteknik_NNP AB_NNP ,_, a_DT company_NN of_IN which_WDT Professor_NNP Uhln_NNP is_VBZ the_DT sole_JJ Director_NNP and_CC shareholder_NN ,_, of_IN SEK_NNP 800,000_CD ,_, with_IN an_DT additional_JJ SEK_NNP 400,000_CD accrued_VBN payments_NNS at_IN December_NNP 2002_CD ._.
These_DT payments_NNS were_VBD made_VBN in_IN respect_NN of_IN royalty_NN agreements_NNS entered_VBD into_IN prior_RB to_TO the_DT appointment_NN of_IN Professor_NNP Uhln_NNP as_IN a_DT Non-Executive_JJ Director_NNP ._.
Loan_NN to_TO Dr_NNP A_NNP Carr_NNP In_IN 2000_CD ,_, the_DT group_NN provided_VBD an_DT interest_NN free_JJ ,_, secured_JJ loan_NN facility_NN to_TO Dr_NNP A_NNP Carr_NNP ,_, the_DT Chief_NNP Executive_NNP of_IN Amersham_NNP Biosciences_NNP ,_, of_IN $_$ 300,000_CD to_TO assist_VB in_IN the_DT purchase_NN of_IN a_DT house_NN following_VBG his_PRP$ relocation_NN to_TO the_DT US_NNP ._.
The_DT loan_NN was_VBD repayable_JJ over_IN five_CD years_NNS in_IN equal_JJ fortnightly_RB instalments_NNS or_CC on_IN his_PRP$ ceasing_VBG to_TO be_VB employed_VBN by_IN the_DT group_NN ,_, if_IN earlier_JJR ._.
The_DT maximum_NN balance_NN on_IN this_DT loan_NN in_IN the_DT year_NN was_VBD $_$ 291,000_CD ._.
The_DT loan_NN has_VBZ been_VBN repaid_VBN since_IN the_DT year_NN end_NN ._.
35_CD Contingent_JJ liabilities_NNS The_DT group_NN is_VBZ involved_VBN in_IN various_JJ negotiations_NNS or_CC disputes_NNS of_IN a_DT nature_NN considered_VBN typical_JJ for_IN its_PRP$ businesses_NNS ,_, including_VBG those_DT relating_VBG to_TO product_NN liability_NN and_CC infringements_NNS and_CC claims_NNS of_IN intellectual_JJ property_NN rights_NNS ,_, validity_NN of_IN patents_NNS and_CC taxation_NN ._.
Although_IN there_EX can_MD be_VB no_DT assurance_NN regarding_VBG the_DT outcome_NN of_IN any_DT of_IN these_DT negotiations_NNS or_CC disputes_NNS ,_, the_DT group_NN believes_VBZ that_IN on_IN the_DT basis_NN of_IN current_JJ available_JJ information_NN they_PRP will_MD not_RB have_VB a_DT material_NN adverse_JJ impact_NN on_IN the_DT groups_NNS financial_JJ position_NN ._.
36_CD Restatement_NN of_IN prior_JJ periods_NNS Following_VBG the_DT introduction_NN of_IN Financial_NNP Reporting_NNP Standard_NNP 19_CD ,_, Deferred_NNP Taxation_NNP in_IN 2002_CD ,_, the_DT group_NN has_VBZ changed_VBN its_PRP$ accounting_NN policy_NN with_IN respect_NN to_TO deferred_VBN taxation_NN ._.
Under_IN the_DT previous_JJ policy_NN ,_, provision_NN was_VBD made_VBN for_IN deferred_VBN taxation_NN ,_, using_VBG the_DT liability_NN method_NN ,_, on_IN all_DT material_NN timing_NN differences_NNS to_TO the_DT extent_NN that_IN it_PRP was_VBD probable_JJ that_IN an_DT asset_NN or_CC liability_NN would_MD crystallise_VB ._.
Under_IN the_DT revised_VBN accounting_NN policy_NN ,_, liabilities_NNS will_MD be_VB recognized_VBN for_IN most_JJS types_NNS of_IN timing_NN differences_NNS regardless_RB of_IN whether_IN they_PRP are_VBP anticipated_VBN to_TO reverse_VB in_IN the_DT foreseeable_JJ future_NN ._.
Deferred_JJ taxation_NN assets_NNS will_MD be_VB recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN they_PRP will_MD reverse_VB ._.
The_DT adjustments_NNS required_VBN to_TO shareholders_NNS funds_NNS are_VBP set_VBN out_RP below_IN :_: 12_CD months_NNS 12_CD months_NNS to_TO 31_CD Dec_NNP to_TO 31_CD Dec_NNP 2001_CD 2001_CD m_NN m_NN Adjustment_NNP to_TO opening_VBG shareholders_NNS funds_NNS 8.5_CD Effect_NN of_IN adoption_NN of_IN FRS19_CD at_IN 1_CD January_NNP 2001_CD 12.3_CD Reverse_VB deferred_VBN tax_NN provision_NN under_IN SSAP_NNP 15_CD 4.5_CD Deferred_JJ tax_NN provision_NN under_IN FRS_NNP 19_CD 9.0_CD Attributable_JJ to_TO minority_NN interest_NN FRS_NNP 19_CD 0.4_CD 3.8_CD Adjustment_NNP to_TO closing_VBG shareholders_NNS funds_NNS 4.4_CD 8.5_CD In_IN the_DT year_NN ended_VBD 31_CD December_NNP 2001_CD ,_, deferred_VBN tax_NN charged_VBN under_IN FRS_NNP 19_CD amounted_VBD to_TO 9.0_CD m_NN :_: this_DT would_MD have_VB been_VBN 4.5_CD m_NN under_IN SSAP_NNP 15_CD ._.
For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, deferred_VBN tax_NN charged_VBN under_IN FRS_NNP 19_CD amounted_VBD to_TO 23.1_CD m_NN :_: this_DT would_MD have_VB been_VBN 18.9_CD m_NN under_IN SSAP_NNP 15_CD ._.
37_CD Post_NNP balance_NN sheet_NN events_NNS On_IN 26_CD February_NNP 2003_CD the_DT group_NN announced_VBD a_DT restructuring_NN of_IN its_PRP$ discovery_NN systems_NNS business_NN area_NN ._.
The_DT restructuring_NN program_NN ,_, which_WDT will_MD deliver_VB a_DT more_RBR efficient_JJ manufacturing_NN cost_NN base_NN and_CC focus_NN research_NN and_CC development_NN on_IN fewer_JJR sites_NNS ,_, will_MD result_VB in_IN the_DT loss_NN of_IN approximately_RB 400_CD jobs_NNS ._.
The_DT group_NN will_MD incur_VB one_CD off_RP costs_NNS in_IN the_DT range_NN of_IN 45-50m_JJ ,_, which_WDT is_VBZ expected_VBN to_TO result_VB in_IN savings_NNS running_VBG at_IN the_DT rate_NN of_IN 30-35m_JJ per_IN annum_NN by_IN the_DT end_NN of_IN 2004_CD ._.
86_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD
